var title_f10_39_10864="Fetal cardiac output distributi";
var content_f10_39_10864=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F70458&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F70458&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 537px\">",
"   <div class=\"ttl\">",
"    Fetal cardiac circulation: Distribution of right (RVO) and left (LVO) ventricular output",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 517px; height: 410px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Shown is the distribution of right and left ventricular output (RVO, LVO) and the combined cardiac output (CCO) in the circulation of the fetal lamb. The largest proportion of the CCO is distributed to the placenta for oxygenation. Through preferential streaming, well oxygenated left ventricular blood supplies the brain and heart, while right ventricular blood (with lower oxygen content) is predominantly distributed to the placenta.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from : Fetal cardiology. Yagel S, Silverman NH, Gembruch U (Eds), Taylor &amp; Francis, Oxford, UK 2003. p.125. Copyright &copy; 2003 Taylor and Francis.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_39_10864=[""].join("\n");
var outline_f10_39_10864=null;
var title_f10_39_10865="Acute portal vein thrombus CT";
var content_f10_39_10865=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F78815&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F78815&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acute portal vein thrombus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 254px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Contrast-enhanced CT scan of the liver in a 27-year-old woman with a systemic coagulation disorder demonstrates a large thrombus in the portal vein (large arrow) which is preventing contrast from entering the main portal vein. The liver is being perfused via hepatic arteries (small arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Krukal, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_39_10865=[""].join("\n");
var outline_f10_39_10865=null;
var title_f10_39_10866="Subperiosteal xanthomata";
var content_f10_39_10866=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F71083&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F71083&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Subperiosteal xanthomata",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 266px; height: 386px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Subperiosteal xanthomata in a patient with heterozygous familial hypercholesterolemia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Durrington P. Dyslipidaemia. Lancet 2003; 362:717. Copyright &copy; 2003 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_39_10866=[""].join("\n");
var outline_f10_39_10866=null;
var title_f10_39_10867="Closure rectovaginal fistula4";
var content_f10_39_10867=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F55071&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F55071&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Repair of a small rectovaginal fistula through a transvaginal approach",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 359px; height: 532px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Closure of the vaginal mucosa.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_39_10867=[""].join("\n");
var outline_f10_39_10867=null;
var title_f10_39_10868="Oxymetholone: Drug information";
var content_f10_39_10868=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Oxymetholone: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?9/3/9269?source=see_link\">",
"    see \"Oxymetholone: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709188\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F205251\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Anadrol&reg;-50",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F205273\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Anabolic Steroid",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F205253\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     The National Kidney Foundation does not recommend the use of androgens as an adjuvant to ESA treatment in anemic patients with chronic kidney disease (KDOQI, 2006).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     <b>",
"      Erythropoietic effects:",
"     </b>",
"     Oral: 1-5 mg/kg/day once daily; usual effective dose: 1-2 mg/kg/day; give for a minimum trial of 3-6 months because response may be delayed",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F205264\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F205254\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F205255\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Mild-to-moderate hepatic impairment: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Severe hepatic impairment: Use is contraindicated.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F205239\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Anadrol&reg;-50: 50 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F205222\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F205275\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-III",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F205241\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of anemias caused by deficient red cell production",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F205279\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Oxymetholone may be confused with oxymetazoline, oxymorphone",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F205271\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Coronary artery disease, peripheral edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Chills, excitation, insomnia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Acne, hirsutism (women), hyperpigmentation, male-pattern baldness (postpubertal males, women)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Amenorrhea, clitoromegaly, glucose tolerance decreased, gynecomastia, HDL-cholesterol decreased, hypercalcemia, hyperchloremia, hyperkalemia, hypernatremia, hyperphosphatemia, LDL-cholesterol increased, libido increased/decreased, menstrual irregularities, virilism (women)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Bladder irritability, epididymitis, impotence, oligospermia, penile enlargement, penile erections increased (prepubertal males), priapism, prostate cancer, prostatic hyperplasia (elderly males), seminal volume decreased, testicular atrophy, testicular dysfunction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Bleeding, INR increased, iron-deficiency anemia, leukemia, prothrombin time increased, clotting factors (II, V, VII, X) suppressed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Alkaline phosphatase increased, bilirubin increased, cholestatic hepatitis, cholestatic jaundice, hepatic failure, hepatic necrosis, hepatocellular carcinoma, liver cell tumors, peliosis hepatis, transaminases increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Creatine phosphokinase increased, premature closure of epiphysis (children)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Creatinine increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Hoarseness (women)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Voice deepening (women)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F205243\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to oxymetholone or any component of the formulation; breast cancer in men; breast cancer in women with hypercalcemia; prostate cancer; severe hepatic dysfunction; nephrosis or nephrotic phase of nephritis; pregnancy or use in women who may become pregnant",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F205226\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Blood lipid changes:",
"     <b>",
"      [U.S. Boxed Warning]: Anabolic steroids may cause changes in blood lipids (decreased high density lipoproteins and sometimes increased low density lipoproteins), increasing the risk of arteriosclerosis and coronary artery disease.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Clotting factor alterations: Anabolic steroids may suppress factors II, V, VII, and X; prothrombin time may be increased.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic effects:",
"     <b>",
"      [U.S. Boxed Warning]: Androgenic anabolic steroid treatment may cause peliosis hepatis,  which occurs when splenic or hepatic tissue is replaced by cysts (blood-filled); may only cause minimal hepatic dysfunction although has been associated with hepatic failure. Androgenic liver cell tumors, which may be benign, although malignant tumors have also been reported; generally regress when anabolic steroid treatment is withdrawn. Both conditions (peliosis and tumors) may not be apparent until liver failure or intra-abdominal hemorrhage develops.",
"     </b>",
"     Androgen use (low doses) has also been associated with cholestatic hepatitis and jaundice; may be associated with hepatomegaly and right upper-quadrant pain; jaundice is typically reversible upon discontinuation (continuing treatment has been associated with coma and death). Monitor liver function periodically.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prostate conditions: Androgenic anabolic steroid use may cause prostatic hypertrophy or prostate cancer in elderly men.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Breast cancer: May cause hypercalcemia in women with breast cancer by stimulating osteolysis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus; insulin or oral hypoglycemic needs may be altered; monitor carefully.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Edematous conditions: Use with caution in patients with conditions influenced by edema (eg, cardiovascular disease, migraine, seizure disorder, renal impairment); may cause fluid retention.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: May accelerate bone maturation without producing compensatory gain in linear growth in children; in prepubertal children perform radiographic examination of the hand and wrist every 6 months to determine the rate of bone maturation and to assess the effect of treatment on the epiphyseal centers.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Women: Discontinue with evidence of mild virilization in women.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299806\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F205231\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Androgens may enhance the hepatotoxic effect of CycloSPORINE (Systemic). Androgens may increase the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Androgens may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F205234\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F205244\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oligospermia or amenorrhea may occur resulting in an impairment of fertility. Use is contraindicated in women who are or may become pregnant.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F205258\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323584\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Anadrol-50 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (100): $3457.49",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F205236\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Periodic liver function tests, lipid profile, hemoglobin and hematocrit; iron studies; serum glucose (may be decreased by testosterone, monitor patients with diabetes); radiologic examination of bones every 6 months (when using in prepubertal children); monitor urine and serum calcium and signs of virilization in women treated for breast cancer",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F205245\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Adroyd (IN);",
"     </li>",
"     <li>",
"      Anapolon (PL);",
"     </li>",
"     <li>",
"      Anasteronal (ES);",
"     </li>",
"     <li>",
"      Androlic (TH);",
"     </li>",
"     <li>",
"      Hemogenin (BR);",
"     </li>",
"     <li>",
"      Oxitosona (ES);",
"     </li>",
"     <li>",
"      Roboral (IL);",
"     </li>",
"     <li>",
"      Synasteron (BE);",
"     </li>",
"     <li>",
"      Zenalosyn (NL)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F205225\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enhances production of erythropoietin in patients with anemias which are due to bone marrow failure; stimulates erythropoiesis in anemias due to deficient red cell production",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      National Kidney Foundation, &ldquo;KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease (2006).&rdquo; Available at   file://www.kidney.org/professionals/KDOQI/guidelines_anemia/index.htm",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9732 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.76.133-192C8F5B95-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_39_10868=[""].join("\n");
var outline_f10_39_10868=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709188\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205251\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205273\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205253\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205264\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205254\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205255\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205239\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205222\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205275\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205241\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205279\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205271\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205243\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205226\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299806\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205231\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205234\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205244\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205258\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323584\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205236\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205245\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205225\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9732\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9732|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?9/3/9269?source=related_link\">",
"      Oxymetholone: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_39_10869="Ulcerative colitis";
var content_f10_39_10869=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Ulcerative colitis (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?10/39/10869/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/39/10869/contributors\" id=\"au6616\">",
"       Mark A Peppercorn, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?10/39/10869/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/39/10869/contributors\" id=\"se6453\">",
"       J Thomas LaMont, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?10/39/10869/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/39/10869/contributors\" id=\"de8151\">",
"       Shilpa Grover, MD, MPH",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?10/39/10869?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      ULCERATIVE COLITIS OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Ulcerative colitis (UC) is a disease in which the lining of the colon (the large intestine) becomes inflamed and develops sores (ulcers), leading to bleeding and diarrhea. The inflammation almost always affects the rectum and lower part of the colon, but it can affect the entire colon (",
"     <a class=\"graphic graphic_figure graphicRef58531 \" href=\"UTD.htm?12/60/13250\">",
"      figure 1",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     Although ulcerative colitis cannot be cured, it can usually be controlled. Most people with ulcerative colitis are able to live active and productive lives. Controlling the disease usually means taking medications and seeing a healthcare provider on a regular basis.",
"    </p>",
"    <p>",
"     This article discusses the causes, symptoms, and treatment of ulcerative colitis. More detailed information about ulcerative colitis is available by subscription. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/7/11386?source=see_link\">",
"      \"Clinical manifestations, diagnosis, and prognosis of ulcerative colitis in adults\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/15/3319?source=see_link\">",
"      \"Management of severe ulcerative colitis\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      ULCERATIVE COLITIS CAUSES",
"     </span>",
"    </p>",
"    <p>",
"     Ulcerative colitis is part of a group of conditions called inflammatory bowel diseases (IBD). Crohn's disease is another inflammatory bowel disease, although it can affect the entire digestive tract (mouth to anus) (",
"     <a class=\"graphic graphic_figure graphicRef66110 \" href=\"UTD.htm?28/27/29107\">",
"      figure 2",
"     </a>",
"     ). Inflammatory bowel disease is NOT the same as irritable bowel syndrome (IBS). (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/40/24196?source=see_link\">",
"      \"Patient information: Crohn's disease (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?3/53/3926?source=see_link\">",
"      \"Patient information: Irritable bowel syndrome (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     The cause of ulcerative colitis is not known. People who develop ulcerative colitis are thought to have an increased risk of the condition, which is passed down from family members. When a person with this inherited risk is exposed to a trigger (an illness or something in the environment), the immune system is activated. The immune system recognizes the lining of the colon as foreign and attacks it, leading to inflammation. This inflammation causes the lining of the colon to develop ulcers and bleed.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Genetics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Ulcerative colitis tends to run in families, suggesting that genetics have a role in this disease. About 10 to 25 percent of people with ulcerative colitis have a first-degree relative (either a sibling or parent) with inflammatory bowel disease (either ulcerative colitis or Crohn's disease).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Environment",
"     </span>",
"     &nbsp;&mdash;&nbsp;Several environmental factors, such as infections, are thought to trigger ulcerative colitis in people who have a genetic susceptibility. However, no single factor has been proven to be the trigger.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      ULCERATIVE COLITIS SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     The symptoms of ulcerative colitis can be mild, moderate, or severe, and can fluctuate over time.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Bowel symptoms",
"     </span>",
"     &nbsp;&mdash;&nbsp;The most common symptoms of mild ulcerative colitis include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Intermittent rectal bleeding",
"      </li>",
"      <li>",
"       Mucus discharge from the rectum",
"      </li>",
"      <li>",
"       Mild diarrhea (defined as fewer than four stools per day)",
"      </li>",
"      <li>",
"       Mild, crampy abdominal pain",
"      </li>",
"      <li>",
"       Straining with bowel movements",
"      </li>",
"      <li>",
"       Bouts of constipation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     In people with moderate to severe disease, the following symptoms can develop:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Frequent, loose bloody stools (up to 10 or more per day)",
"      </li>",
"      <li>",
"       Low blood count (anemia)",
"      </li>",
"      <li>",
"       Abdominal pain, which can be severe",
"      </li>",
"      <li>",
"       Fever",
"      </li>",
"      <li>",
"       Weight loss",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Non-bowel symptoms",
"     </span>",
"     &nbsp;&mdash;&nbsp;For poorly understood reasons, people with ulcerative colitis can develop inflammation outside of the colon. Inflammation often affects large joints (hips, knees), causing swelling and pain, as well as the eyes, the skin, and, less commonly, the lungs.",
"    </p>",
"    <p>",
"     These symptoms usually occur when ulcerative colitis symptoms are active (during a flare). However, inflammation can develop even when symptoms are quiet (in remission).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H8\">",
"     <span class=\"h1\">",
"      ULCERATIVE COLITIS DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     Ulcerative colitis is usually diagnosed based upon your symptoms, a physical examination, and laboratory tests. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/7/11386?source=see_link\">",
"      \"Clinical manifestations, diagnosis, and prognosis of ulcerative colitis in adults\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     You will likely need a procedure that allows your doctor to look inside your colon, such as sigmoidoscopy or colonoscopy. These tests allow your doctor to take tissue samples from the colon, which can confirm ulcerative colitis and rule out other conditions that have similar symptoms, including Crohn's disease, diverticulitis, and certain infections. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/30/9698?source=see_link\">",
"      \"Patient information: Colonoscopy (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?41/12/42176?source=see_link\">",
"      \"Patient information: Flexible sigmoidoscopy (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H9\">",
"     <span class=\"h1\">",
"      ULCERATIVE COLITIS TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     The two main goals of treatment for ulcerative colitis are to:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       End symptoms (achieve remission)",
"      </li>",
"      <li>",
"       Prevent symptoms from coming back (maintain remission)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     For most people, ulcerative colitis has a frustrating pattern of flares and remissions. However, about 15 percent of people who have an initial attack will remain in remission without medications, possibly for the rest of their life. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/15/3319?source=see_link\">",
"      \"Management of severe ulcerative colitis\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Diet and ulcerative colitis",
"     </span>",
"     &nbsp;&mdash;&nbsp;A well-balanced, nutritious diet can help maintain health and a normal body weight. However, many people can identify foods that worsen symptoms, and it is reasonable to avoid these foods. Table 1 lists foods and beverages that worsen symptoms in some people (",
"     <a class=\"graphic graphic_table graphicRef79547 \" href=\"UTD.htm?8/39/8828\">",
"      table 1",
"     </a>",
"     ). If you restrict your diet for any reason, you should take a daily multivitamin. A folic acid supplement is also recommended.",
"    </p>",
"    <p>",
"     Pain medications that contain nonsteroidal antiinflammatory drugs (NSAIDS), such as ibuprofen (Advil&reg;, Motrin&reg;) and naproxen (Aleve&reg;), are not usually recommended if you have ulcerative colitis. These medications can worsen symptoms. Acetaminophen (Tylenol&reg;) should not cause a problem.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h3\">",
"      Lactose intolerance",
"     </span>",
"     &nbsp;&mdash;&nbsp;Lactose intolerance can occur in people with ulcerative colitis. It occurs if you are not able to digest the sugar (lactose) contained in milk products. Symptoms of lactose intolerance may include diarrhea, cramps, or gas. The symptoms of lactose intolerance can be minimized by avoiding dairy products (",
"     <a class=\"graphic graphic_table graphicRef55938 \" href=\"UTD.htm?32/38/33388\">",
"      table 2",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Treatments for mild symptoms",
"     </span>",
"     &nbsp;&mdash;&nbsp;If your symptoms include rectal pain, rectal bleeding, and mild diarrhea, your treatment will include medications that you apply to the rectum. This may include an enema, suppository, or foam. Rectal medications include 5-ASA (aminosalicylic acid) or glucocorticoids (also called steroids), which work by reducing inflammation in the rectum and colon. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/11/17586?source=see_link\">",
"      \"Patient information: Sulfasalazine and the 5-aminosalicylates (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Oral medications may be recommended if your symptoms do not improve completely with the rectal treatments. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20344?source=see_link\">",
"      \"Sulfasalazine and 5-aminosalicylates in the treatment of inflammatory bowel disease\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     These treatments improve symptoms in most people after about three weeks. Up to 90 percent of people will have a remission with this treatment, and up to 70 percent of people will stay in remission. Continuous, lifelong treatment with a 5-ASA medication is usually recommended to maintain remission, although it is often possible to taper the dose of medication.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Treatment for moderate to severe symptoms",
"     </span>",
"     &nbsp;&mdash;&nbsp;If your symptoms are moderate to severe, or a larger area of your colon is affected, you will probably be given an oral 5-ASA medication. This is sometimes given along with a rectal treatment.",
"    </p>",
"    <p>",
"     If your symptoms are severe, you may need a glucocorticoid (also called steroid) for a short period of time. Glucocorticoids can be given rectally, in a foam or suppository, or as a pill. The pill is generally preferred for treating severe symptoms. When your symptoms quiet, you will probably stop the oral steroid pill, but you will continue to take one of the oral 5-ASA drugs. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/11/17586?source=see_link\">",
"      \"Patient information: Sulfasalazine and the 5-aminosalicylates (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     When taken by mouth, steroids are very effective but may cause a number of bothersome side effects. The most common side effects include an increased appetite, weight gain, acne, fluid retention, trembling, mood swings, and difficulty sleeping. Because of the risk of these and other side effects, most people are tapered off of steroids as soon as possible.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      If symptoms do not improve",
"     </span>",
"     &nbsp;&mdash;&nbsp;Some people do not respond, or respond incompletely, to the treatments described above. These people are said to have refractory ulcerative colitis. This includes people who depend upon steroids to control their symptoms. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24250?source=see_link\">",
"      \"Approach to adults with steroid-refractory and steroid-dependent ulcerative colitis\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h3\">",
"      Medications",
"     </span>",
"     &nbsp;&mdash;&nbsp;People with refractory ulcerative colitis are usually treated first with medications that suppress the immune system. The most commonly used drugs are 6-mercaptopurine and azathioprine. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/5/21592?source=see_link\">",
"      \"Azathioprine and 6-mercaptopurine in inflammatory bowel disease\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       6-mercaptopurine and azathioprine &ndash; Azathioprine and 6-mercaptopurine lessen symptoms in 60 to 70 percent of people and help to maintain remission and decrease the need for steroids. It may take three to six months to see the greatest benefit.",
"       <br/>",
"       <br/>",
"       If treatment with 6-mercaptopurine and azathioprine is not effective, you may be given a choice between trying another medication, such as cyclosporine or infliximab, and having surgery to remove your colon. (See",
"       <a class=\"local\" href=\"#H16\">",
"        'Ulcerative colitis surgery'",
"       </a>",
"       below.)",
"      </li>",
"      <li>",
"       Cyclosporine &ndash; Cyclosporine is a powerful drug that was designed to prevent rejection after organ transplantation. It can be a very effective treatment to induce remission in people with refractory ulcerative colitis, although it cannot be used long-term (to maintain remission) due to potentially toxic side effects. Once symptoms are under control, other treatments can be slowly substituted.",
"      </li>",
"      <li>",
"       Infliximab and adalimumab &ndash; Infliximab (Remicade&reg;) and adalimumab (Humira&reg;) are powerful medications that have been used to treat Crohn's disease and rheumatoid arthritis, and are sometimes used to treat refractory ulcerative colitis. They can be used to induce remission and, long-term, to maintain remission.",
"       <br/>",
"       <br/>",
"       Infliximab and adalimumab work differently than other treatments for UC. They are in a class of medications known as biologic response modifiers, which work by interfering with pathways involved in inflammation.",
"       <br/>",
"       <br/>",
"       Infliximab and adalimumab may be used alone or in combination with other treatments. Because of the cost and the potential risk of side effects, biologic response agents are generally reserved for people with severe ulcerative colitis who have not responded to steroids, who prefer to avoid surgical removal of the colon, and who cannot take cyclosporine.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H16\">",
"     <span class=\"h1\">",
"      ULCERATIVE COLITIS SURGERY",
"     </span>",
"    </p>",
"    <p>",
"     People who cannot tolerate the constant battle with their disease sometimes choose to have their colon surgically removed. There are several surgical procedures that may be recommended to treat ulcerative colitis. It is important to discuss all of the benefits and risks of surgery with a doctor, and also to have realistic expectations of the results. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/50/4906?source=see_link\">",
"      \"Surgical management of ulcerative colitis\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     The procedures can be divided into two groups:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Those that preserve your ability to control bowel movements",
"      </li>",
"      <li>",
"       Those that require you to wear a bag to collect bowel movements",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Removal of colon with permanent ileostomy",
"     </span>",
"     &nbsp;&mdash;&nbsp;During this procedure, the surgeon removes your colon, rectum, and anus; this is called proctocolectomy. The surgeon then attaches the ileum, or lower end of the small intestine, to an opening (ostomy) on the lower right side of the abdomen near the waistline. Bodily waste now exits your body through the ostomy, rather than through your anus. You will wear a plastic bag on the outside of the ostomy to catch the bowel movements, and you will empty the bag as needed.",
"    </p>",
"    <p>",
"     One variation of this surgery involves creating a sac or pouch inside the lower abdomen to collect stool. Waste empties into this internal pouch. A small, leakproof opening is created in your abdomen so that you can insert a tube to drain the pouch.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h2\">",
"      Removal of colon and reattachment of anus/rectum",
"     </span>",
"     &nbsp;&mdash;&nbsp;This procedure is one of the most common surgeries used to treat ulcerative colitis. During the procedure, the surgeon removes the large bowel and all or most of the rectum, but saves the anal sphincter or lower part of the rectum. The surgeon then creates a tubular pouch out of the end of the small intestine and sews it to the anal canal.",
"    </p>",
"    <p>",
"     This surgery allows you to have bowel movements through the anus, and you will not need a permanent ileostomy. However, in most cases, you will require a temporary ileostomy while the new rectum heals. When the new rectum is healed, the bowel is connected to the anal sphincter.",
"    </p>",
"    <p>",
"     There is a risk of fecal leakage after this procedure, particularly at night. There is also a risk of recurrent ulcerative colitis in the end portion of the rectum.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H19\">",
"     <span class=\"h1\">",
"      COLORECTAL CANCER AND ULCERATIVE COLITIS",
"     </span>",
"    </p>",
"    <p>",
"     People with ulcerative colitis have an increased risk of colorectal cancer. Your risk of colorectal cancer is related to the length of time since you were diagnosed and how much of your colon is affected. In general, people who have had the disease for a longer time and those with larger areas of disease have a greater risk than those with a more recent diagnosis or smaller areas of disease.",
"    </p>",
"    <p>",
"     Colorectal cancer usually develops from precancerous changes in the colon, which grow slowly and can be detected with a screening test, such as colonoscopy. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/23/7541?source=see_link\">",
"      \"Patient information: Colon and rectal cancer screening (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     In general, colonoscopy is recommended 8 to 12 years after your symptoms appear. If this colonoscopy is normal, it is usually repeated once per year. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/7/25722?source=see_link\">",
"      \"Colorectal cancer surveillance in inflammatory bowel disease\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H20\">",
"     <span class=\"h1\">",
"      PREGNANCY AND ULCERATIVE COLITIS",
"     </span>",
"    </p>",
"    <p>",
"     A separate article discusses pregnancy and UC. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?5/20/5443?source=see_link\">",
"      \"Patient information: Inflammatory bowel disease and pregnancy (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H21\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1784850640\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14336834\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?41/17/42258?source=see_link\">",
"      Patient information: Ulcerative colitis in adults (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/34/25123?source=see_link\">",
"      Patient information: Colon and rectal cancer screening (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/38/11875?source=see_link\">",
"      Patient information: Colostomy care (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/9/38034?source=see_link\">",
"      Patient information: Colectomy (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?28/28/29122?source=see_link\">",
"      Patient information: Pyoderma gangrenosum (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/24/20866?source=see_link\">",
"      Patient information: Erythema nodosum (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/59/40882?source=see_link\">",
"      Patient information: Ileostomy care (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/33/38418?source=see_link\">",
"      Patient information: Ulcerative colitis in children (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14336884\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/40/24196?source=see_link\">",
"      Patient information: Crohn's disease (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?3/53/3926?source=see_link\">",
"      Patient information: Irritable bowel syndrome (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/30/9698?source=see_link\">",
"      Patient information: Colonoscopy (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?41/12/42176?source=see_link\">",
"      Patient information: Flexible sigmoidoscopy (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/11/17586?source=see_link\">",
"      Patient information: Sulfasalazine and the 5-aminosalicylates (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/23/7541?source=see_link\">",
"      Patient information: Colon and rectal cancer screening (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?5/20/5443?source=see_link\">",
"      Patient information: Inflammatory bowel disease and pregnancy (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H22\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/1/26647?source=see_link\">",
"      Anti-tumor necrosis factor therapy in ulcerative colitis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/34/20008?source=see_link\">",
"      Antibiotics for treatment of inflammatory bowel diseases",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25289?source=see_link\">",
"      Arthritis associated with gastrointestinal disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/5/21592?source=see_link\">",
"      Azathioprine and 6-mercaptopurine in inflammatory bowel disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/7/11386?source=see_link\">",
"      Clinical manifestations, diagnosis, and prognosis of ulcerative colitis in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/25/40342?source=see_link\">",
"      Colorectal cancer and primary sclerosing cholangitis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/7/25722?source=see_link\">",
"      Colorectal cancer surveillance in inflammatory bowel disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/17/7450?source=see_link\">",
"      Definition, epidemiology, and risk factors in inflammatory bowel disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14089?source=see_link\">",
"      Endoscopic diagnosis of inflammatory bowel disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/14/25834?source=see_link\">",
"      Fertility, pregnancy, and nursing in inflammatory bowel disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/26/44455?source=see_link\">",
"      Genetic factors in inflammatory bowel disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/31/22006?source=see_link\">",
"      Hepatobiliary manifestations of inflammatory bowel disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/36/22090?source=see_link\">",
"      Management of mild to moderate ulcerative colitis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/15/3319?source=see_link\">",
"      Management of severe ulcerative colitis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20344?source=see_link\">",
"      Sulfasalazine and 5-aminosalicylates in the treatment of inflammatory bowel disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/50/4906?source=see_link\">",
"      Surgical management of ulcerative colitis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/30/18920?source=see_link\">",
"      Toxic megacolon",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/34/4650?source=see_link\">",
"      Treatment of ulcerative colitis in children and adolescents",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24250?source=see_link\">",
"      Approach to adults with steroid-refractory and steroid-dependent ulcerative colitis",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Diabetes and Digestive and Kidney Diseases",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.niddk.nih.gov/\">",
"      www.niddk.nih.gov/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The American Society of Colon and Rectal Surgeons",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.fascrs.org/\">",
"      www.fascrs.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The American Gastroenterological Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.gastro.org/\">",
"      www.gastro.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Crohn's and Colitis Foundation of America",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.ccfa.org/\">",
"      www.ccfa.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?10/39/10869/abstract/1-4\">",
"      1-4",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 17, 2013.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?10/39/10869?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10869/abstract/1\">",
"      Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults. American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 1997; 92:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10869/abstract/2\">",
"      Connell WR, Kamm MA, Dickson M, et al. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet 1994; 343:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10869/abstract/3\">",
"      Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987; 317:1625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10869/abstract/4\">",
"      Cohen RD, Woseth DM, Thisted RA, Hanauer SB. A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol 2000; 95:1263.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f10_39_10869=[""].join("\n");
var outline_f10_39_10869=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           ULCERATIVE COLITIS OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           ULCERATIVE COLITIS CAUSES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           ULCERATIVE COLITIS SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H8\">",
"           ULCERATIVE COLITIS DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H9\">",
"           ULCERATIVE COLITIS TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H16\">",
"           ULCERATIVE COLITIS SURGERY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H19\">",
"           COLORECTAL CANCER AND ULCERATIVE COLITIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H20\">",
"           PREGNANCY AND ULCERATIVE COLITIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H21\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/60/13250\" title=\"figure 1\">",
"           Diagram colon rectum PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/27/29107\" title=\"figure 2\">",
"           Digestive system adult PI",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?8/39/8828\" title=\"table 1\">",
"           Food intolerances IBD PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?32/38/33388\" title=\"table 2\">",
"           Lactose content of different foods PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f10_39_10870="Glipizide: Pediatric drug information";
var content_f10_39_10870=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Glipizide: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?39/28/40391?source=see_link\">",
"    see \"Glipizide: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?16/19/16693?source=see_link\">",
"    see \"Glipizide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F176326\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Glucotrol XL&reg;;",
"     </li>",
"     <li>",
"      Glucotrol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1058904\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antidiabetic Agent, Oral",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antidiabetic Agent, Sulfonylurea",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Hypoglycemic Agent, Oral",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1058897\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?39/28/40391?source=see_link\">",
"      see \"Glipizide: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Management of noninsulin-dependent diabetes mellitus in patients",
"     <b>",
"      previously untreated:",
"     </b>",
"     Initial: 5 mg/day immediate release or extended release tablets; adjust dosage in 2.5-5 mg daily increments in intervals of 3-7 days for immediate release tablets or 5 mg daily increments in intervals of at least 7 days for extended release tablets; if total daily dose for immediate release tablets is &gt;15 mg, divide into twice daily dosage; maximum daily dose for immediate release tablets: 40 mg; maximum daily dose for extended release tablets: 20 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Patients may be converted from immediate release tablets to extended release tablets by giving the nearest equivalent total daily dose once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Management of noninsulin-dependent diabetes mellitus in patients",
"     <b>",
"      previously maintained on insulin:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Insulin dosage &le;20 units/day: Use recommended initial dose and abruptly discontinue insulin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Insulin dosage &gt;20 units/day: Use recommended initial dose and reduce daily insulin dosage by 50%; continue to withdraw daily insulin dosage gradually over several days as tolerated with incremental increases of glipizide",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment/comments in renal impairment:",
"     </b>",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Some investigators recommend not using",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"     Reduce initial dosage to 2.5 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F176300\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 5 mg, 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Glucotrol&reg;: 5 mg, 10 mg [scored; dye free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral: 2.5 mg, 5 mg, 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Glucotrol XL&reg;: 2.5 mg, 5 mg, 10 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F176286\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1058909\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer immediate release tablets 30 minutes before a meal; extended release tablets should be swallowed whole and administered with breakfast; do not cut, crush, or chew",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1058900\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at room temperature; protect from light",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1058908\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of type II diabetes mellitus (noninsulin-dependent, NIDDM) when hyperglycemia cannot be managed by diet alone; may be used concomitantly with metformin or insulin to improve glycemic control",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F176378\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       GlipiZIDE may be confused with glimepiride, glyBURIDE",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Glucotrol&reg; may be confused with Glucophage&reg;, Glucotrol&reg; XL, glyBURIDE",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F176376\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Syncope",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Anxiety, depression, dizziness, drowsiness, headache, hypoesthesia, insomnia, nervousness, pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Eczema, erythema, maculopapular eruptions, morbilliform eruptions, pruritus, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypoglycemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, constipation, diarrhea, dyspepsia, flatulence, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Alkaline phosphatase increased, AST increased, LDH increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, leg cramps, myalgia, paresthesia, tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Blood urea nitrogen increased, creatinine increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Rhinitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Agranulocytosis, anorexia, aplastic anemia, arrhythmia, blood in stool, cholestatic jaundice, conjunctivitis, disulfiram-like reaction, edema, gait instability, hemolytic anemia, hypertension, hypertonia, hyponatremia, jaundice, leukopenia, liver injury, migraine, pancytopenia, photosensitivity, porphyria, retinal hemorrhage, SIADH, thrombocytopenia, vertigo",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1058913\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to glipizide, any component, or other sulfonamides; type 1 diabetes mellitus (insulin-dependent, IDDM), diabetic ketoacidosis with or without coma",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1058896\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with adrenal or pituitary insufficiency; hypoglycemic reactions are more prevalent in debilitated, malnourished patients, patients with mild disease or impaired hepatic or renal function; hypoglycemia may also occur with inadequate caloric intake, strenuous exercise, or concurrent use with other hypoglycemic drugs; use of extended release formulation in patients with markedly reduced GI retention time eg, short-bowel syndrome, may potentially result in lower plasma levels and decreased effect",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1058895\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Chemical similarities are present among sulfonamides, sulfonylureas, carbonic anhydrase inhibitors, thiazides, and loop diuretics (except ethacrynic acid), and although only glipizide use in patients with sulfonamide allergy is specifically contraindicated in product labeling, there is a risk of cross-reaction in patients with allergies to any of these compounds; avoid use when the previous reaction has been severe; product labeling states oral hypoglycemic drugs may be associated with an increased cardiovascular mortality as compared to treatment with diet alone or diet plus insulin; data to support this association are limited, and several studies, including a large prospective trial (UKPDS) have not supported an association",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F176365\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C9 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F176295\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): Sulfonylureas may enhance the adverse/toxic effect of Alcohol (Ethyl). A flushing reaction may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: May enhance the hypoglycemic effect of Sulfonylureas. Cardioselective beta-blockers (eg, acebutolol, atenolol, metoprolol, and penbutolol) may be safer than nonselective beta-blockers. All beta-blockers appear to mask tachycardia as an initial symptom of hypoglycemia. Ophthalmic beta-blockers are probably associated with lower risk than systemic agents.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chloramphenicol: May decrease the metabolism of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May increase the serum concentration of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clarithromycin: May increase the serum concentration of GlipiZIDE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colesevelam: May decrease the serum concentration of GlipiZIDE. Management: Administer glipizide at least 4 hours prior to colesevelam.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyclic Antidepressants: May enhance the hypoglycemic effect of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inducers (Strong): May increase the metabolism of CYP2C9 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Moderate): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Strong): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fibric Acid Derivatives: May enhance the hypoglycemic effect of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May increase the serum concentration of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GLP-1 Agonists: May enhance the hypoglycemic effect of Sulfonylureas. Management: Consider sulfonylurea dose reductions when used in combination with GLP-1 agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypoglycemic Properties): May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: May enhance the adverse/toxic effect of other Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May diminish the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Luteinizing Hormone-Releasing Hormone Analogs: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP2C9 Substrates. Management: Use CYP2C9 substrates at the lowest recommended dose, and monitor closely for adverse effects, during and in the 2 weeks following mifepristone treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: May enhance the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Posaconazole: May enhance the hypoglycemic effect of GlipiZIDE. Posaconazole may increase the serum concentration of GlipiZIDE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May decrease the protein binding of Sulfonylureas. Probenecid may increase the serum concentration of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: May enhance the hypoglycemic effect of Sulfonylureas. This appears to be particularly concerning early in the course of combination therapy. Quinolone Antibiotics may diminish the hypoglycemic effect of Sulfonylureas. With longer-term combination, there is a greater risk of hyperglycemia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranitidine: May increase the serum concentration of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: May increase the metabolism of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Hypoglycemic Agents. Management: Consider increased monitoring of glycemic control with concomitant use of a hypoglycemic agent and an SSRI. Dosage adjustments of the hypoglycemic agent may be necessary upon SSRI initiation or discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Somatropin: May diminish the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonamide Derivatives: May enhance the hypoglycemic effect of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Sulfonylureas may enhance the anticoagulant effect of Vitamin K Antagonists. Vitamin K Antagonists may enhance the hypoglycemic effect of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May increase the serum concentration of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1058916\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food delays absorption but does not affect the extent of absorption or peak levels achieved",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F176296\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F176311\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in animal studies; therefore, glipizide is classified as pregnancy category C. Glipizide crosses the placenta. Severe hypoglycemia lasting 4-10 days has been noted in infants born to mothers taking a sulfonylurea at the time of delivery. Maternal hyperglycemia can be associated with adverse effects in the fetus, including macrosomia, neonatal hyperglycemia, and hyperbilirubinemia; the risk of congenital malformations is increased when the Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     is above the normal range. Diabetes can also be associated with adverse effects in the mother. Poorly-treated diabetes may cause end-organ damage that may in turn negatively affect obstetric outcomes. Physiologic glucose levels should be maintained prior to and during pregnancy to decrease the risk of adverse events in the mother and the fetus. Until additional safety and efficacy data are obtained, the use of oral agents is generally not recommended as routine management of GDM or type 2 diabetes mellitus during pregnancy. The manufacturer recommends if glipizide is used during pregnancy it should be discontinued at least 1 month before the expected delivery date. Insulin is the drug of choice for the control of diabetes mellitus during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1058903\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Signs and symptoms of hypoglycemia, fasting blood glucose, glycosylated hemoglobin (hemoglobin A",
"     <sub>",
"      1c",
"     </sub>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1058907\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Target range:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Blood glucose: Fasting and preprandial: 80-120 mg/dL; bedtime: 100-140 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Glycosylated hemoglobin (hemoglobin A",
"     <sub>",
"      1c",
"     </sub>",
"     ): &lt;7%",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1058894\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stimulates insulin release from the pancreatic beta cells, reduces glucose output from the liver, and increases insulin sensitivity at peripheral target sites",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1058911\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Immediate release formulation: 15-30 minutes; extended release formulation: 2-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum effect: Immediate release formulation: Within 2-3 hours; extended release formulation: 6-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Immediate release formulation: 12-24 hours; extended release formulation: 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Average decrease in fasting blood glucose (when used as monotherapy): 60-70 mg/dL",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1058912\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid and complete",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : Adults: 10 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 98% to 99%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensive liver metabolism to inactive metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 80% to 100%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: Adults: 2-5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Immediate release formulation: 1-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Extended release formulation: 6-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: &lt;10% of drug excreted into urine as unchanged drug; 90% of drug excreted as metabolites in urine and 10% excreted in feces",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1058902\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?16/19/16693?source=see_link\">",
"      see \"Glipizide: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not change dose or discontinue without consulting prescriber; avoid alcohol while taking this medication, may cause severe reaction; maintain regular dietary intake and exercise routine; always carry quick source of sugar; if experiencing a hypoglycemic reaction, contact prescriber immediately; report severe or persistent side effects, extended vomiting or flu-like symptoms, skin rash, easy bruising or bleeding, or change in color of urine or stool; when taking extended release tablets, it is not unusual to observe a tablet in the stool; this is the nonabsorbable shell containing the active drug which has been released. May rarely cause photosensitivity reactions (eg, exposure to sunlight may cause severe sunburn, skin rash, redness, or itching); avoid direct exposure to sunlight",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1058914\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     When transferring from other sulfonylurea antidiabetic agents to glyburide, with the exception of chlorpropamide, the administration of the other agent may be abruptly discontinued; due to the prolonged elimination half-life of chlorpropamide, a 2- to 3-day drug-free interval may be advisable before glipizide therapy is begun",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      DeFronzo RA, &ldquo;Pharmacologic Therapy for Type 2 Diabetes Mellitus,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1999, 131(4):281-303.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/39/10870/abstract-text/ 10454950 /pubmed\" id=\" 10454950 \" target=\"_blank\">",
"        10454950",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Intensive Blood-Glucose Control With Sulphonylureas or Insulin Compared With Conventional Treatment and Risk of Complications in Patients With Type 2 Diabetes (UKPDS 33) UK Prospective Diabetes Study (UKPDS) Group,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1998, 352(9131):837-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/39/10870/abstract-text/9742976 /pubmed\" id=\"9742976 \" target=\"_blank\">",
"        9742976",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13334 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-197.136.42.3-E7729EB691-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_39_10870=[""].join("\n");
var outline_f10_39_10870=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176326\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058904\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058897\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176300\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176286\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058909\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058900\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058908\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176378\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176376\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058913\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058896\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058895\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176365\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176295\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058916\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176296\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176311\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058903\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058907\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058894\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058911\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058912\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058902\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058914\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13334\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13334|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?39/28/40391?source=related_link\">",
"      Glipizide: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?16/19/16693?source=related_link\">",
"      Glipizide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_39_10871="Adenosarcoma";
var content_f10_39_10871=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F70818&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F70818&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Uterine adensosarcoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William Mann, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_39_10871=[""].join("\n");
var outline_f10_39_10871=null;
var title_f10_39_10872="Use of the signal-averaged electrocardiogram in arrhythmia evaluation and management";
var content_f10_39_10872=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Use of the signal-averaged electrocardiogram in arrhythmia evaluation and management",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/39/10872/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/39/10872/contributors\">",
"     Sanjiv M Narayan, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/39/10872/contributors\">",
"     Michael E Cain, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/39/10872/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/39/10872/contributors\">",
"     Ary L Goldberger, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/39/10872/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/39/10872/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/39/10872/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sudden cardiac death affects over 400,000 individuals per year in the United States alone, predominantly from ventricular tachycardia (VT) or ventricular fibrillation (VF) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10872/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The signal-averaged electrocardiogram (SAECG) is a noninvasive technique that enables detection of the substrate for reentrant arrhythmias, particularly ventricular tachycardia.",
"   </p>",
"   <p>",
"    In patients with the substrate for VT, slow conduction through myocardium disrupted by inflammation, edema, fibrosis, or scar tissue results in electrical potentials that extend beyond the activation time of normal surrounding myocardium, but which are too small for detection on the surface ECG [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10872/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. The SAECG uses computerized averaging of ECG complexes, obtained during sinus rhythm, to facilitate the detection of these small microvolt level signals, recorded as ventricular late potentials (",
"    <a class=\"graphic graphic_figure graphicRef72380 \" href=\"UTD.htm?19/22/19808\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/50/13093?source=see_link\">",
"     \"Technical aspects of the signal-averaged electrocardiogram\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The potential clinical applications for the SAECG are diverse. An American College of Cardiology (ACC) consensus task force provided a guide to the settings in which the SAECG is of proven value, possible value, and not indicated [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10872/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will review the use of the SAECG with an emphasis on the efficacy of antiarrhythmic medications, evaluation of the results of arrhythmia surgery, and identification of individuals with paroxysmal atrial fibrillation prone to frequent recurrences based upon abnormalities in the P-wave SAECG [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10872/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. The use of the SAECG in other settings is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/18/4391?source=see_link\">",
"     \"Clinical applications of the signal-averaged electrocardiogram: Overview\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/51/36661?source=see_link\">",
"     \"Use of the signal-averaged electrocardiogram in nonischemic heart disease and cardiac transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/57/27544?source=see_link\">",
"     \"Use of the signal-averaged electrocardiogram in ischemic heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PREDICTING THE EFFICACY OF ANTIARRHYTHMIC DRUGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although anti-arrhythmic drug efficacy is typically assessed by absence of recurrent arrhythmias, the SAECG offers an a priori method to assess drug efficacy. Several studies have tested the hypothesis that abnormalities on the SAECG evolve with the arrhythmogenic substrate, and thus diminish with successful antiarrhythmic therapy, in parallel with reduced risk for ventricular arrhythmias. As expected, changes in the SAECG correlate poorly with the clinical efficacy of anti-arrhythmic drugs that have not been shown to abolish late potentials [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10872/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/23/3448?source=see_link\">",
"     \"Pharmacologic therapy in survivors of sudden cardiac arrest\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, the effects of antiarrhythmic drugs on the SAECG are class-specific:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Class IA and IC, but not class IB antiarrhythmic drugs (",
"      <a class=\"graphic graphic_table graphicRef56600 \" href=\"UTD.htm?2/52/2892\">",
"       table 1",
"      </a>",
"      ) alter the characteristics of late potentials and may artifactually create them through nonspecific prolongation of the low-amplitude terminal QRS region [",
"      <a class=\"abstract\" href=\"UTD.htm?10/39/10872/abstract/10-15\">",
"       10-15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Prolongation in the filtered QRS duration is more marked with class IC than IA agents [",
"      <a class=\"abstract\" href=\"UTD.htm?10/39/10872/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The effect of class III drugs on the SAECG is controversial.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       Amiodarone",
"      </a>",
"      has been shown to increase filtered QRS duration, prolong late potential duration, and reduce RMS voltage in the terminal QRS complex in some, but not all, studies [",
"      <a class=\"abstract\" href=\"UTD.htm?10/39/10872/abstract/16-19\">",
"       16-19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In general, beta blockers (class II) and calcium channel blockers (class IV) do not alter the SAECG.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Mechanistically, the physiologic importance of drug-related ECG changes is uncertain. Some studies suggest that slow conduction in sinus rhythm indicated by late potentials correlates with slow conduction during reentrant VT. For example, the Electrophysiologic Study Versus Electrocardiographic Monitoring (ESVEM) study found that patients whose VT was effectively suppressed by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    had a shorter QRS duration than those in whom sotalol was ineffective [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10872/abstract/20\">",
"     20",
"    </a>",
"    ]. Further study is required to determine whether this result represents lack of efficacy or even proarrhythmia from sotalol in patients with conduction abnormalities",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ventricular scar [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10872/abstract/21\">",
"     21",
"    </a>",
"    ]. Conversely, changes on the SAECG related to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    may not correlate with drug efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10872/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/10/28841?source=see_link\">",
"     \"Therapeutic use and major side effects of sotalol\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Frequency domain analysis of the SAECG may also predict effective antiarrhythmic therapy. Specifically, the terminal",
"    <span class=\"nowrap\">",
"     QRS/ST",
"    </span>",
"    segment and the entire cardiac cycle exhibit altered spectral magnitudes in patients receiving successful antiarrhythmic drug regimens compared to those in whom therapy was unsuccessful [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10872/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. In one study, for example, spectral turbulence analysis had a sensitivity and specificity of 86 and 70 percent, respectively, for predicting the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    in patients with healed myocardial infarction and inducible monomorphic VT [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10872/abstract/25\">",
"     25",
"    </a>",
"    ]. Conversely, a separate report revealed that spectrotemporal SAECG analysis was unchanged in patients with inducible sustained VT before and after therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10872/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/50/13093?source=see_link\">",
"     \"Technical aspects of the signal-averaged electrocardiogram\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Data from ESVEM and other studies suggest that patients with slower VT may also show slower conduction during sinus rhythm (longer QRS duration and late potentials on the SAECG) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10872/abstract/10,26\">",
"     10,26",
"    </a>",
"    ]. Furthermore, some clinical series have shown that the prolongation in QRS duration from class I agents correlates with a longer VT cycle length [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10872/abstract/6,10-12,15\">",
"     6,10-12,15",
"    </a>",
"    ]. Indirectly, these data support the concept that slow conduction during sinus rhythm, measured from the SAECG, determines dynamic conduction velocity and tissue wavelength of reentry during VT. Since reentry also requires heterogeneous repolarization, studies have also correlated SAECG abnormalities with prolonged ventricular repolarization or refractoriness in patients with ventricular arrhythmias. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/62/42984?source=see_link\">",
"     \"Reentry and the development of cardiac arrhythmias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Summary for predicting drug efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American College of Cardiology (ACC) consensus task force considered the SAECG a promising, but currently unproven, tool for determining the efficacy or proarrhythmic effects of antiarrhythmic drugs in patients with ventricular arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10872/abstract/5\">",
"     5",
"    </a>",
"    ]. Since methodology may significantly affect the detection of class-specific effects of antiarrhythmic medications on the SAECG, this usage requires additional research prior to routine clinical use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DETERMINING THE SUCCESS OF ANATOMICAL ARRHYTHMIA THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies have examined whether the SAECG can predict whether monomorphic ventricular tachycardia has been eliminated, or its episodes rendered less frequent, via surgical ablation of an automatic focus or resection of myocardium critical to the development or maintenance of reentry. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/52/13129?source=see_link\">",
"     \"Catheter ablation for ventricular arrhythmias\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Notably, surgical, catheter, and transcoronary ethanol ablation for VT have been associated with a reduced incidence of late potentials on the post-procedure SAECG [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10872/abstract/7,27,28\">",
"     7,27,28",
"    </a>",
"    ]. Therefore, the SAECG may help guide postablative clinical management since the absence of late potentials correlates well with the inability to induce VT after surgical resection. Approximately 90 percent of patients with a normal post-surgical SAECG do not have inducible VT. Conversely, late potentials are present in 85 to 100 percent of patients in whom VT remains inducible.",
"   </p>",
"   <p>",
"    Data are beginning to emerge that support the prognostic utility of the SAECG in patients undergoing percutaneous catheter ablation. This is particularly pertinent in the wake of the SMASH-VT study, in which catheter ablation at regions of intra-ventricular late potentials reduced the incidence of ICD therapy on long-term follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10872/abstract/29\">",
"     29",
"    </a>",
"    ]. In a study of18 patients with arrhythmogenic right ventricular cardiomyopathy, elimination of late ventricular potentials by radiofrequency ablation predicted arrhythmia-free survival after a mean of 5 years follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10872/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/52/13129?source=see_link\">",
"     \"Catheter ablation for ventricular arrhythmias\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Late potentials may persist in up to 56 percent of patients after curative resection, suggesting that residual areas of slow conduction may persist despite the successful resection of arrhythmogenic tissue. This supports one hypothesis that the SAECG reflects structural, rather than functional, substrates for VT [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10872/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/18/4391?source=see_link\">",
"     \"Clinical applications of the signal-averaged electrocardiogram: Overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Summary for predicting efficacy of ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ACC consensus task force concluded that the SAECG is valuable for assessing the clinical efficacy of surgical ablation for VT [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10872/abstract/5\">",
"     5",
"    </a>",
"    ]. However, further supportive evidence is required before firm recommendations can be made.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     P-WAVE SAECG AND ATRIAL FIBRILLATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reentrant arrhythmias in the atrium, analogous to those in the ventricle, also likely require heterogeneities in slow conduction and repolarization. This provides a theoretical basis for prediction of the propensity for atrial fibrillation (AF) by SAECG by examining slow conduction in the atrium, analogous to the detection of ventricular late potentials. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/62/42984?source=see_link\">",
"     \"Reentry and the development of cardiac arrhythmias\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/42/26278?source=see_link\">",
"     \"The electrocardiogram in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The P-wave SAECG recorded during sinus rhythm has therefore been developed to identify:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Patients with paroxysmal AF",
"     </li>",
"     <li>",
"      The frequency and duration of recurrent episodes of AF",
"     </li>",
"     <li>",
"      Patients at risk for developing AF.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Paroxysmal AF",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with paroxysmal AF may be identified by P-wave prolongation on the SAECG during sinus rhythm, although the threshold P-wave duration that best discriminates such patients is controversial. A vector P-wave duration of 155 ms predicted AF with a sensitivity, specificity, and positive predictive accuracy of 80, 93, and 92 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10872/abstract/32\">",
"     32",
"    </a>",
"    ]. Vector P-wave thresholds of 120 ms and 140 ms have been suggested in other studies [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10872/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. Unlike the ventricle, the utility of atrial late potentials in the terminal 10 to 20 ms of the P-wave remains controversial. It is also unclear whether low RMS voltage at the P-wave terminus indicates AF risk independent of structural heart disease or left atrial dilatation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10872/abstract/8,33,35\">",
"     8,33,35",
"    </a>",
"    ]. Studies have shown that prolonged atrial conduction times (ie, slow conduction), particularly when challenged at rapid rates, may uncover substrates that enable AF to form and that may be used to further refine the P-wave SAECG [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10872/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. In particular, a bi-atrial mapping study showed that the site of AF initiation typically shows slow conduction at rapid rates, but not at baseline, just prior to AF onset [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10872/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Frequency domain criteria have also been developed for the atrial SAECG. Specifically, increased spectral magnitude in the 20 to 50 Hz bandwidth in the terminal P-wave may identify patients with propensity for AF [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10872/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/50/13093?source=see_link\">",
"     \"Technical aspects of the signal-averaged electrocardiogram\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Transition to chronic AF",
"    </span>",
"    &nbsp;&mdash;&nbsp;It remains unproven whether the risk for recurrent or sustained episodes of AF can be predicted from the P-wave SAECG. In one series, 122 patients with paroxysmal AF were followed for 26 months [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10872/abstract/39\">",
"     39",
"    </a>",
"    ]. An SAECG P-wave duration greater than 145 ms and terminal 30 ms P-wave voltage less than 3.0 mV indicated a significantly greater risk of progression to chronic AF (defined as AF sustained for six months) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10872/abstract/39\">",
"     39",
"    </a>",
"    ]. Other studies have correlated frequent episodes of AF (more than one per month) with longer P-wave duration, but not with P-wave late potentials [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10872/abstract/40\">",
"     40",
"    </a>",
"    ]. The ability of the P-wave SAECG to predict the development of chronic AF therefore remains unclear. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/41/31384?source=see_link\">",
"     \"Paroxysmal atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Development of AF",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preliminary data suggest that the development of AF can be predicted using analyses of the P-wave from the SAECG in certain patient populations (",
"    <a class=\"graphic graphic_figure graphicRef60431 \" href=\"UTD.htm?25/2/25645\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10872/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. For example, in patients undergoing elective cardiac surgery, P-wave duration greater than 155 ms provided a sensitivity, specificity, and positive and negative predictive accuracy for the development of AF of 69, 79, 69, and 82 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10872/abstract/41\">",
"     41",
"    </a>",
"    ]. Some studies suggest that analysis of the P-wave SAECG predicts the propensity to AF more accurately than left atrial dimensions [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10872/abstract/43\">",
"     43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28602?source=see_link\">",
"     \"Atrial fibrillation and flutter after cardiac surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    P-wave prolongation may also predict AF in patients post-myocardial infarction or with hypertrophic cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10872/abstract/39,44\">",
"     39,44",
"    </a>",
"    ]. Among patients with hypertrophic cardiomyopathy, the combination of a P wave duration of 140 ms and left atrial enlargement (&gt;40 mm) has been associated with a specificity and positive predictive accuracy for AF of 93 and 78 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10872/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A sub-study analysis of MADIT II found that abnormalities of P wave shape in orthogonal X, Y and Z axis ECGs predicted AF onset and sudden cardiac arrest in 802 patients with ischemic cardiomyopathy and left ventricular ejection fraction &le;30 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10872/abstract/45\">",
"     45",
"    </a>",
"    ]. However, the traditional SAECG indices of P wave duration and terminal amplitude did not predict AF onset or sudden cardiac arrest. These results suggest a wider significance of the P wave than is generally recognized, perhaps as an indicator of atrial enlargement from ventricular dysfunction, and warrant further study. In a related study, P wave morphology changed over time in patients from the MADIT II study who later developed AF, but remained unchanged in those who did not [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10872/abstract/46\">",
"     46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19657?source=see_link\">",
"     \"Implantable cardioverter-defibrillators: Clinical trials of primary prevention of sudden cardiac death\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Recurrence of AF after cardioversion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The P-wave SAECG may also predict those patients who will experience recurrent AF early after cardioversion. Observations from a study of 32 patients followed for one year after cardioversion included the following [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10872/abstract/47\">",
"     47",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among patients not taking antiarrhythmic drugs, those with recurrent arrhythmia within three months had a longer P-wave duration (148 versus 135 ms in those without recurrence).",
"     </li>",
"     <li>",
"      P wave duration of 130 ms correctly classified 85 percent of patients with a sensitivity and specificity of 81 and 89 percent, respectively.",
"     </li>",
"     <li>",
"      The predictive value of the P wave duration is poor in patients receiving antiarrhythmic drugs, possibly due to changes in the atrial refractory period.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Detection of accessory pathway",
"    </span>",
"    &nbsp;&mdash;&nbsp;Accessory pathways may reveal no evidence of preexcitation on the surface ECG during normal sinus rhythm and therefore appear \"concealed.\". Since supraventricular tachycardias utilizing such pathways may have narrow QRS complexes, their distinction from atrioventricular (AV) nodal reentrant tachycardia may be difficult. The P wave signal averaged ECG may identify such patients. In one report, patients with a concealed left-sided accessory pathway had a more prolonged filtered P wave duration during sinus rhythm than controls or patients with AV nodal reentrant tachycardia (132 versus 19 ms) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10872/abstract/48\">",
"     48",
"    </a>",
"    ]. Although patients with AF also have a prolonged P wave duration, analysis of the P-wave frequency component (AR20 or power spectrum area in the 0 to 20 Hz zone divided by that in the 20 to 100 Hz zone) distinguished patients with AF from those with an accessory pathway (3.2 versus 1.7). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/21/39256?source=see_link\">",
"     \"Anatomy, pathophysiology and localization of accessory pathways in the preexcitation syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Summary for predicting atrial fibrillation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although not addressed by the ACC consensus task force, the P-wave SAECG is a promising tool to predict the propensity for AF independent of structural heart disease, although its clinical efficacy has not been established. Although the P-wave duration is reproducible, its spectra may not be. Moreover, the P-wave SAECG is affected by autonomic tone and technical fidelity in its measurement require improvement before its widespread use can be recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10872/abstract/49-51\">",
"     49-51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18456623\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The signal-averaged electrocardiogram (SAECG) is a noninvasive technique that enables detection of the substrate for reentrant arrhythmias, particularly ventricular tachycardia (VT). In patients with the substrate for VT, slow conduction through myocardium disrupted by inflammation, edema, fibrosis, or scar tissue results in electrical potentials that extend beyond the activation time of normal surrounding myocardium, but which are too small for detection on the surface ECG. The SAECG uses computerized averaging of ECG complexes, obtained during sinus rhythm, to facilitate the detection of these small microvolt level signals, recorded as ventricular late potentials (",
"      <a class=\"graphic graphic_figure graphicRef72380 \" href=\"UTD.htm?19/22/19808\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several studies have tested the hypothesis that abnormalities on the SAECG evolve with the arrhythmogenic substrate and thus diminish with successful antiarrhythmic therapy, in parallel with reduced risk for ventricular arrhythmias. Changes in the SAECG correlate poorly with the clinical efficacy of anti-arrhythmic drugs that have not been shown to abolish late potentials; thus, the effects of antiarrhythmic drugs on the SAECG are class-specific. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Predicting the efficacy of antiarrhythmic drugs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surgical, catheter, and transcoronary ethanol ablation for VT have been associated with a reduced incidence of late potentials on the post-procedure SAECG. Therefore, the SAECG may help guide postablative clinical management since the absence of late potentials correlates well with the inability to induce VT after surgical resection. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Determining the success of anatomical arrhythmia therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Reentrant arrhythmias in the atrium, analogous to those in the ventricle, also likely require heterogeneities in slow conduction and repolarization. This provides a theoretical basis for prediction of the propensity for atrial fibrillation by using SAECG on the P-wave to detect slow conduction in the atrium, analogous to the detection of ventricular late potentials. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'P-wave SAECG and atrial fibrillation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10872/abstract/1\">",
"      Bay&eacute;s de Luna A, Coumel P, Leclercq JF. Ambulatory sudden cardiac death: mechanisms of production of fatal arrhythmia on the basis of data from 157 cases. Am Heart J 1989; 117:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10872/abstract/2\">",
"      Zheng ZJ, Croft JB, Giles WH, Mensah GA. Sudden cardiac death in the United States, 1989 to 1998. Circulation 2001; 104:2158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10872/abstract/3\">",
"      El-Sherif N, Scherlag BJ, Lazzara R, Hope RR. Re-entrant ventricular arrhythmias in the late myocardial infarction period. 1. Conduction characteristics in the infarction zone. Circulation 1977; 55:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10872/abstract/4\">",
"      Pogwizd SM, Hoyt RH, Saffitz JE, et al. Reentrant and focal mechanisms underlying ventricular tachycardia in the human heart. Circulation 1992; 86:1872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10872/abstract/5\">",
"      Signal-averaged electrocardiography. J Am Coll Cardiol 1996; 27:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10872/abstract/6\">",
"      Freedman RA, Steinberg JS. Selective prolongation of QRS late potentials by sodium channel blocking antiarrhythmic drugs: relation to slowing of ventricular tachycardia. Electrophysiologic Study Versus Electrocardiographic Monitoring Trial (ESVEM) Investigators. J Am Coll Cardiol 1991; 17:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10872/abstract/7\">",
"      Denniss AR, Johnson DC, Richards DA, et al. Effect of excision of ventricular myocardium on delayed potentials detected by the signal-averaged electrocardiogram in patients with ventricular tachycardia. Am J Cardiol 1987; 59:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10872/abstract/8\">",
"      Ehlert FA, Steinberg JS. The P wave signal-averaged ECG. J Electrocardiol 1995; 28 Suppl:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10872/abstract/9\">",
"      Denniss AR, Ross DL, Richards DA, et al. Effect of antiarrhythmic therapy on delayed potentials detected by the signal-averaged electrocardiogram in patients with ventricular tachycardia after acute myocardial infarction. Am J Cardiol 1986; 58:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10872/abstract/10\">",
"      Hopson JR, Kienzle MG, Aschoff AM, Shirkey DR. Noninvasive prediction of efficacy of type IA antiarrhythmic drugs by the signal-averaged electrocardiogram in patients with coronary artery disease and sustained ventricular tachycardia. Am J Cardiol 1993; 72:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10872/abstract/11\">",
"      Kulakowski P, Bashir Y, Heald S, et al. Effects of procainamide on the signal-averaged electrocardiogram in relation to the results of programmed ventricular stimulation in patients with sustained monomorphic ventricular tachycardia. J Am Coll Cardiol 1993; 21:1428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10872/abstract/12\">",
"      Greenspon AJ, Kidwell GA, DeCaro M, Hessen S. The effects of type I antiarrhythmic drugs on the signal-averaged electrocardiogram in patients with malignant ventricular arrhythmias. Pacing Clin Electrophysiol 1992; 15:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10872/abstract/13\">",
"      Takanaka C, Nonokawa M, Machii T, et al. Mexiletine and propafenone: a comparative study of monotherapy, low, and full dose combination therapy. Pacing Clin Electrophysiol 1992; 15:2130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10872/abstract/14\">",
"      Lombardi F, Finocchiaro ML, Dalla Vecchia L, et al. Effects of mexiletine, propafenone and flecainide on signal-averaged electrocardiogram. Eur Heart J 1992; 13:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10872/abstract/15\">",
"      Kulakowski P, Gibson S, Ward J, Camm AJ. Flecainide-related alterations in the signal-averaged electrocardiogram: similarity between patients with or without ventricular tachycardia. Eur Heart J 1992; 13:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10872/abstract/16\">",
"      Denniss AR, Richards DA, Cody DV, et al. Prognostic significance of ventricular tachycardia and fibrillation induced at programmed stimulation and delayed potentials detected on the signal-averaged electrocardiograms of survivors of acute myocardial infarction. Circulation 1986; 74:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10872/abstract/17\">",
"      Kulakowski P, Bashir Y, Heald S, et al. Prediction of antiarrhythmic efficacy of class I and III agents in patients with ventricular tachycardia by signal-averaged ECG analysis. Pacing Clin Electrophysiol 1992; 15:2116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10872/abstract/18\">",
"      Borbola J, Denes P. Oral amiodarone loading therapy. I. The effect on serial signal-averaged electrocardiographic recordings and the QTc in patients with ventricular tachyarrhythmias. Am Heart J 1988; 115:1202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10872/abstract/19\">",
"      Goedel-Meinen L, Hofmann M, Schmidt G, et al. Amiodarone--efficacy and late potentials during long-term therapy. Int J Clin Pharmacol Ther Toxicol 1990; 28:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10872/abstract/20\">",
"      Freedman RA, Karagounis LA, Steinberg JS. Effects of sotalol on the signal-averaged electrocardiogram in patients with sustained ventricular tachycardia: relation to suppression of inducibility and changes in tachycardia cycle length. J Am Coll Cardiol 1992; 20:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10872/abstract/21\">",
"      Waldo AL, Camm AJ, deRuyter H, et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol. Lancet 1996; 348:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10872/abstract/22\">",
"      Cain ME, Ambos HD, Witkowski FX, Sobel BE. Fast-Fourier transform analysis of signal-averaged electrocardiograms for identification of patients prone to sustained ventricular tachycardia. Circulation 1984; 69:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10872/abstract/23\">",
"      Wolzt M, Schmetterer L, Kastner J, et al. Short-term drug effects on the signal-averaged electrocardiogram in healthy men: assessment of intra- and interindividual variability of spectral temporal mapping and time-domain analysis. J Pharmacol Exp Ther 1995; 275:1375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10872/abstract/24\">",
"      Cain ME, Ambos HD, Osborn JL, et al. Therapeutic implications of spectral alterations in ECGs induced by antiarrhythmic drugs (abstract). Circulation 1990; 82:III354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10872/abstract/25\">",
"      Fetsch T, et al. Is the efficacy of sotalol treatment predictable by the analysis of spectral turbulences from the signal-averaged ECG? (abstract). Circulation 1993; 88(Suppl) I:I.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10872/abstract/26\">",
"      Anderson KP, Bigger JT Jr, Freedman RA. Electrocardiographic predictors in the ESVEM trial: unsustained ventricular tachycardia, heart period variability, and the signal-averaged electrocardiogram. Prog Cardiovasc Dis 1996; 38:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10872/abstract/27\">",
"      Marcus NH, Falcone RA, Harken AH, et al. Body surface late potentials: effects of endocardial resection in patients with ventricular tachycardia. Circulation 1984; 70:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10872/abstract/28\">",
"      Dailey SM, Kay GN, Epstein AE, Plumb VJ. Modification of late potentials by intracoronary ethanol infusion. Pacing Clin Electrophysiol 1992; 15:1646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10872/abstract/29\">",
"      Reddy VY, Reynolds MR, Neuzil P, et al. Prophylactic catheter ablation for the prevention of defibrillator therapy. N Engl J Med 2007; 357:2657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10872/abstract/30\">",
"      Oginosawa Y, Nogami A, Soejima K, et al. Effect of cardiac resynchronization therapy in isolated ventricular noncompaction in adults: follow-up of four cases. J Cardiovasc Electrophysiol 2008; 19:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10872/abstract/31\">",
"      Breithardt G, Borggrefe M, Karbenn U, Schwarzmaier J. Effects of pharmacological and non-pharmacological interventions on ventricular late potentials. Eur Heart J 1987; 8 Suppl A:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10872/abstract/32\">",
"      Guidera SA, Steinberg JS. The signal-averaged P wave duration: a rapid and noninvasive marker of risk of atrial fibrillation. J Am Coll Cardiol 1993; 21:1645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10872/abstract/33\">",
"      Fukunami M, Yamada T, Ohmori M, et al. Detection of patients at risk for paroxysmal atrial fibrillation during sinus rhythm by P wave-triggered signal-averaged electrocardiogram. Circulation 1991; 83:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10872/abstract/34\">",
"      Chang AC, Winkler JB, Fananapazir L. P wave signal-averaging identifies hypertrophic cardiomyopathy patients with paroxysmal atrial fibrillation [abstract]. J Am Coll Cardiol 1990; 15:191A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10872/abstract/35\">",
"      Stafford PJ, Turner I, Vincent R. Quantitative analysis of signal-averaged P waves in idiopathic paroxysmal atrial fibrillation. Am J Cardiol 1991; 68:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10872/abstract/36\">",
"      Roberts-Thomson KC, Stevenson IH, Kistler PM, et al. Anatomically determined functional conduction delay in the posterior left atrium relationship to structural heart disease. J Am Coll Cardiol 2008; 51:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10872/abstract/37\">",
"      Lalani GG, Schricker A, Gibson M, et al. Atrial conduction slows immediately before the onset of human atrial fibrillation: a bi-atrial contact mapping study of transitions to atrial fibrillation. J Am Coll Cardiol 2012; 59:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10872/abstract/38\">",
"      Yamada T, Fukunami M, Ohmori M, et al. Characteristics of frequency content of atrial signal-averaged electrocardiograms during sinus rhythm in patients with paroxysmal atrial fibrillation. J Am Coll Cardiol 1992; 19:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10872/abstract/39\">",
"      Abe Y, Fukunami M, Yamada T, et al. Prediction of transition to chronic atrial fibrillation in patients with paroxysmal atrial fibrillation by signal-averaged electrocardiography: a prospective study. Circulation 1997; 96:2612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10872/abstract/40\">",
"      Iwakura K, Abe Y, Ohmori M, et al. Relationship between frequency and duration of paroxysmal atrial fibrillation attacks and atrial late potentials (abstract). Circulation 1992; 86(Suppl I):I131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10872/abstract/41\">",
"      Klein M, Evans SJ, Blumberg S, et al. Use of P-wave-triggered, P-wave signal-averaged electrocardiogram to predict atrial fibrillation after coronary artery bypass surgery. Am Heart J 1995; 129:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10872/abstract/42\">",
"      Zaman AG, Archbold RA, Helft G, et al. Atrial fibrillation after coronary artery bypass surgery: a model for preoperative risk stratification. Circulation 2000; 101:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10872/abstract/43\">",
"      Stafford PJ, Kolvekar S, Cooper J, et al. Signal averaged P wave compared with standard electrocardiography or echocardiography for prediction of atrial fibrillation after coronary bypass grafting. Heart 1997; 77:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10872/abstract/44\">",
"      Cecchi F, Montereggi A, Olivotto I, et al. Risk for atrial fibrillation in patients with hypertrophic cardiomyopathy assessed by signal averaged P wave duration. Heart 1997; 78:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10872/abstract/45\">",
"      Holmqvist F, Platonov PG, McNitt S, et al. Abnormal P-wave morphology is a predictor of atrial fibrillation development and cardiac death in MADIT II patients. Ann Noninvasive Electrocardiol 2010; 15:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10872/abstract/46\">",
"      Holmqvist F, Platonov PG, Carlson J, et al. Altered interatrial conduction detected in MADIT II patients bound to develop atrial fibrillation. Ann Noninvasive Electrocardiol 2009; 14:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10872/abstract/47\">",
"      Raitt MH, Ingram KD, Thurman SM. Signal-averaged P wave duration predicts early recurrence of atrial fibrillation after cardioversion. Pacing Clin Electrophysiol 2000; 23:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10872/abstract/48\">",
"      Yoshida T, Ikeda H, Hiraki T, et al. Detection of concealed left sided accessory atrioventricular pathway by P wave signal averaged electrocardiogram. J Am Coll Cardiol 1999; 33:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10872/abstract/49\">",
"      Stafford PJ, Cooper J, Fothergill J, et al. Reproducibility of the signal averaged P wave: time and frequency domain analysis. Heart 1997; 77:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10872/abstract/50\">",
"      Cheema AN, Ahmed MW, Kadish AH, Goldberger JJ. Effects of autonomic stimulation and blockade on signal-averaged P wave duration. J Am Coll Cardiol 1995; 26:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10872/abstract/51\">",
"      Stafford PJ, Cooper J, Garratt CJ. Improved recovery of high frequency P wave energy by selective P wave averaging. Pacing Clin Electrophysiol 1996; 19:1225.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 957 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.150.3.100-CF9877BBA9-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_39_10872=[""].join("\n");
var outline_f10_39_10872=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18456623\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PREDICTING THE EFFICACY OF ANTIARRHYTHMIC DRUGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Summary for predicting drug efficacy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DETERMINING THE SUCCESS OF ANATOMICAL ARRHYTHMIA THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Summary for predicting efficacy of ablation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      P-WAVE SAECG AND ATRIAL FIBRILLATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Paroxysmal AF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Transition to chronic AF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Development of AF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Recurrence of AF after cardioversion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Detection of accessory pathway",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Summary for predicting atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18456623\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/957\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/957|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/22/19808\" title=\"figure 1\">",
"      Positive SAECG following myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/2/25645\" title=\"figure 2\">",
"      SAECG predicts atrial fibrillation post CABG",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/957|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/52/2892\" title=\"table 1\">",
"      Vaughan Williams classification of antiarrhythmic drugs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/21/39256?source=related_link\">",
"      Anatomy, pathophysiology and localization of accessory pathways in the preexcitation syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28602?source=related_link\">",
"      Atrial fibrillation and flutter after cardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/52/13129?source=related_link\">",
"      Catheter ablation for ventricular arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/18/4391?source=related_link\">",
"      Clinical applications of the signal-averaged electrocardiogram: Overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19657?source=related_link\">",
"      Implantable cardioverter-defibrillators: Clinical trials of primary prevention of sudden cardiac death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/41/31384?source=related_link\">",
"      Paroxysmal atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/23/3448?source=related_link\">",
"      Pharmacologic therapy in survivors of sudden cardiac arrest",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/62/42984?source=related_link\">",
"      Reentry and the development of cardiac arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/50/13093?source=related_link\">",
"      Technical aspects of the signal-averaged electrocardiogram",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/42/26278?source=related_link\">",
"      The electrocardiogram in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/10/28841?source=related_link\">",
"      Therapeutic use and major side effects of sotalol",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/57/27544?source=related_link\">",
"      Use of the signal-averaged electrocardiogram in ischemic heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/51/36661?source=related_link\">",
"      Use of the signal-averaged electrocardiogram in nonischemic heart disease and cardiac transplantation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_39_10873="Budesonide (systemic therapy and oral inhalation): Drug information";
var content_f10_39_10873=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Budesonide (systemic therapy and oral inhalation): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?24/45/25303?source=see_link\">",
"    see \"Budesonide (systemic therapy and oral inhalation): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/36/21064?source=see_link\">",
"    see \"Budesonide (systemic therapy and oral inhalation): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F7998594\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Entocort&reg; EC;",
"     </li>",
"     <li>",
"      Pulmicort Flexhaler&reg;;",
"     </li>",
"     <li>",
"      Pulmicort Respules&reg;;",
"     </li>",
"     <li>",
"      Uceris&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F7998595\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Entocort&reg;;",
"     </li>",
"     <li>",
"      Pulmicort&reg; Turbuhaler&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F7998598\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Corticosteroid, Inhalant (Oral);",
"     </li>",
"     <li>",
"      Corticosteroid, Systemic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F7998725\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Asthma:",
"     </b>",
"     <b>",
"      Oral inhalation:",
"     </b>",
"     Titrate to lowest effective dose once patient is stable.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      <b>",
"       <i>",
"        U.S. labeling:",
"       </i>",
"      </b>",
"     </i>",
"     Pulmicort Flexhaler&reg;: Initial: 360 mcg twice daily (selected patients may be initiated at 180 mcg twice daily); maximum: 720 mcg twice daily;",
"     <b>",
"      Note:",
"     </b>",
"     May increase dose after 1-2 weeks of therapy in patients who are not adequately controlled:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      NIH Asthma Guidelines (NIH, 2007)",
"     </i>",
"     (administer in divided doses twice daily):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &ldquo;Low&rdquo; dose: 180-600 mcg/day",
"    </p>",
"    <p style=\"text-indent:2em;margin-left:4em;text-align:justify;\">",
"     &ldquo;Medium&rdquo; dose: &gt;600-1200 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &ldquo;High&rdquo; dose: &gt;1200 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Canadian labeling:",
"      </i>",
"     </b>",
"     Pulmicort&reg; Turbuhaler&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Initial (or during periods of severe asthma or when switching from oral corticosteroid therapy): 400-2400 mcg daily in 2-4 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Maintenance: 200-400 mcg twice daily (higher doses may be needed for some patients). Patients taking 400 mcg/day may take as a single daily dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Conversion from oral systemic corticosteroid to orally inhaled corticosteroid:",
"     </b>",
"     Initiation of oral inhalation therapy should begin in patients whose asthma is reasonably stabilized on oral corticosteroids (OCS). A gradual dose reduction of OCS should begin ~7-10 days after starting inhaled therapy. U.S. labeling recommends reducing prednisone dose by 2.5 mg/day (or equivalent of other OCS) on a weekly basis (patients using oral inhaler) or by &le;25% every 1-2 weeks (patients using respules). Canadian labeling recommends reducing prednisone dose by 2.5 mg/day (or equivalent of other OCS) every 4 days in closely monitored patients or every 10 days if not closely monitored. If adrenal insufficiency occurs, temporarily increase the OCS dose and follow with a more gradual withdrawal.",
"     <b>",
"      Note:",
"     </b>",
"     When transitioning from systemic to inhaled corticosteroids, supplemental systemic corticosteroid therapy may be necessary during periods of stress or during severe asthma attacks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Crohn's disease (active):",
"     </b>",
"     <b>",
"      Oral:",
"     </b>",
"     Capsule: 9 mg once daily in the morning for up to 8 weeks; recurring episodes may be treated with a repeat 8-week course of treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maintenance of remission: Following treatment of active disease (control of symptoms with CDAI &lt;150), treatment may be continued at a dosage of 6 mg once daily for up to 3 months. If symptom control is maintained for 3 months, tapering of the dosage to complete cessation is recommended. Continued dosing beyond 3 months has not been demonstrated to result in substantial benefit.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Ulcerative colitis (active):",
"     </b>",
"     Oral: Tablet: 9 mg once daily in the morning for up to 8 weeks",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F7998724\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/36/21064?source=see_link\">",
"      see \"Budesonide (systemic therapy and oral inhalation): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Asthma:",
"     </b>",
"     Titrate to lowest effective dose once patient is stable.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Oral inhalation:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      <i>",
"       U.S. labeling:",
"      </i>",
"     </b>",
"     Pulmicort Flexhaler&reg;: Children &ge;6 years: Initial: 180 mcg twice daily (some patients may be initiated at 360 mcg twice daily); maximum: 360 mcg twice daily;",
"     <b>",
"      Note:",
"     </b>",
"     May increase dose after 1-2 weeks of therapy in patients who are not adequately controlled.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      NIH Asthma Guidelines (NIH, 2007)",
"     </i>",
"     (administer in divided doses twice daily):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;text-align:justify;\">",
"     Children 5-11 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     &ldquo;Low&rdquo; dose: 180-400 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     &ldquo;Medium&rdquo; dose: &gt;400-800 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     &ldquo;High&rdquo; dose: &gt;800 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;text-align:justify;\">",
"     Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Canadian labeling:",
"      </i>",
"     </b>",
"     Pulmicort&reg; Turbuhaler&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 6-11 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Initial (or during periods of severe asthma or when switching from oral corticosteroid therapy): 200-400 mcg daily in 2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Maintenance: Individualized, lowest effective dose in 2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Conversion from oral systemic corticosteroid to orally inhaled corticosteroid:",
"     </b>",
"     Initiation of oral inhalation therapy should begin in patients whose asthma is reasonably stabilized on oral corticosteroids (OCS). A gradual dose reduction of OCS should begin ~7-10 days after starting inhaled therapy. U.S. labeling recommends reducing prednisone dose by 2.5 mg/day (or equivalent of other OCS) on a weekly basis (patients using oral inhaler) or by &le;25% every 1-2 weeks (patients using respules). Canadian labeling recommends reducing prednisone dose by 2.5 mg/day (or equivalent of other OCS) every 4 days in closely monitored patients or every 10 days if not closely monitored. If adrenal insufficiency occurs, temporarily increase the OCS dose and follow with a more gradual withdrawal.",
"     <b>",
"      Note:",
"     </b>",
"     When transitioning from systemic to inhaled corticosteroids, supplemental systemic corticosteroid therapy may be necessary during periods of stress or during severe asthma attacks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Nebulization:",
"     </b>",
"     Pulmicort Respules&reg;: Children 12 months to 8 years: Titrate to lowest effective dose once patient is stable; start at 0.25 mg/day or use as follows:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Previous therapy of bronchodilators alone: 0.5 mg/day administered as a single dose or divided twice daily (maximum daily dose: 0.5 mg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Previous therapy of inhaled corticosteroids: 0.5 mg/day administered as a single dose or divided twice daily (maximum daily dose: 1 mg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Previous therapy of oral corticosteroids: 1 mg/day administered as a single dose or divided twice daily (maximum daily dose: 1 mg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      NIH Asthma Guidelines (NIH, 2007):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Children 0-4 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;text-align:justify;\">",
"     &ldquo;Low&rdquo; dose: 0.25-0.5 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;text-align:justify;\">",
"     &ldquo;Medium&rdquo; dose: &gt;0.5-1 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;text-align:justify;\">",
"     &ldquo;High&rdquo; dose: &gt;1 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Children 5-11 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;text-align:justify;\">",
"     &ldquo;Low&rdquo; dose: 0.5 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;text-align:justify;\">",
"     &ldquo;Medium&rdquo; dose: 1 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;text-align:justify;\">",
"     &ldquo;High&rdquo; dose: 2 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F7998726\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F14311016\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhalation, Nebulization, Oral: No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F7998727\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhalation, Nebulization, Oral: No specific dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied). Manufacturer labeling for oral budesonide suggests a dosage reduction may be necessary with moderate to severe impairment. Budesonide undergoes hepatic metabolism; bioavailability increased in cirrhosis; monitor closely for signs and symptoms of hypercorticism.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F7998744\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, enteric coated, oral: 3 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Entocort&reg; EC: 3 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder, for oral inhalation:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pulmicort Flexhaler&reg;: 90 mcg/inhalation (165 mg) [contains lactose; delivers ~80 mcg/inhalation; 60 actuations]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pulmicort Flexhaler&reg;: 180 mcg/inhalation (225 mg) [contains lactose; delivers ~160 mcg/inhalation; 120 actuations]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, for nebulization: 0.25 mg/2 mL (30s); 0.5 mg/2 mL (30s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pulmicort Respules&reg;: 0.25 mg/2 mL (30s); 0.5 mg/2 mL (30s); 1 mg/2 mL (30s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Uceris&trade;: 9 mg",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F7998745\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for oral inhalation:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pulmicort&reg; Turbuhaler&reg;: 100 mcg/inhalation [delivers 200 metered actuations]; 200 mcg/inhalation [delivers 200 metered actuations]; 400 mcg/inhalation [delivers 200 metered actuations]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F7998596\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Capsule; suspension for nebulization",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F7998729\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral capsule, tablet: May be administered without regard to meals. Swallow whole; do not crush, chew, or break.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for inhalation:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pulmicort Flexhaler&reg;: Hold inhaler in upright position (mouthpiece up) to load dose. Do not shake prior to use. Unit should be primed prior to first use only. It will not need primed again, even if not used for a long time. Place mouthpiece between lips and inhale forcefully and deeply. Do not exhale through inhaler; do not use a spacer. Dose indicator does not move with every dose, usually only after 5 doses. Discard when dose indicator reads &ldquo;0&rdquo;. Rinse mouth with water after each use to reduce incidence of candidiasis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pulmicort&reg; Turbuhaler&reg; [CAN, not available in the U.S.]: Hold inhaler in upright position (mouthpiece up) to load dose. Do not shake inhaler after dose is loaded. Unit should be primed prior to first use. Place mouthpiece between lips and inhale forcefully and deeply; mouthpiece should face up. Do not exhale through inhaler; do not use a spacer. When a red mark appears in the dose indicator window, 20 doses are left. When the red mark reaches the bottom of the window, the inhaler should be discarded. Rinse mouth with water after use to reduce incidence of candidiasis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension for nebulization: Shake well before using. Use Pulmicort Respules&reg; with jet nebulizer connected to an air compressor; administer with mouthpiece or facemask. Do not use ultrasonic nebulizer. Do not mix with other medications in nebulizer. Rinse mouth following treatments to decrease risk of oral candidiasis (wash face if using face mask).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F7998644\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Nebulization: Maintenance and prophylactic treatment of asthma",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral capsule: Treatment of active Crohn's disease (mild-to-moderate) involving the ileum and/or ascending colon; maintenance of remission (for up to 3 months) of Crohn's disease (mild-to-moderate) involving the ileum and/or ascending colon",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral inhalation: Maintenance and prophylactic treatment of asthma; includes patients who require oral corticosteroids and those who may benefit from systemic dose reduction/elimination",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral tablet: Induction of remission in patients with active ulcerative colitis (mild-to-moderate)",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F7998653\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Oral capsules:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (21%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Bruising (5% to 15%), acne (&lt;5% to 15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Respiratory infection (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Fat redistribution (moon face, buffalo hump; 3% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Edema (&lt;5% to 7%), chest pain (&lt;5%), facial edema (&lt;5%), flushing (&lt;5%), hypertension (&lt;5%), palpitation (&lt;5%), tachycardia (&lt;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (&lt;5% to 7%), agitation (&lt;5%), amnesia (&lt;5%), confusion (&lt;5%), fever (&lt;5%), insomnia (&lt;5%), malaise (&lt;5%), nervousness (&lt;5%), sleep disorder (&lt;5%), somnolence (&lt;5%), vertigo (&lt;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Hirsutism (5%), alopecia (&lt;5%), dermatitis (&lt;5%), eczema (&lt;5%), purpura (&lt;5%), skin disorder (&lt;5%), striae (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypokalemia (&lt;5%), intermenstrual bleeding (&lt;5%), menstrual disorder (&lt;5%), adrenal insufficiency (&ge;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (10%), dyspepsia (6%), anus disorder (&lt;5%), appetite increased (&lt;5%), Crohn's disease exacerbation (&lt;5%), enteritis (&lt;5%), epigastric pain (&lt;5%), gastrointestinal fistula (&lt;5%), glossitis (&lt;5%), hemorrhoids (&lt;5%), intestinal obstruction (&lt;5%), oral candidiasis (&lt;5%), tongue edema (&lt;5%), tooth disorder (&lt;5%), weight gain (&lt;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Dysuria (&lt;5%), micturition frequency (&lt;5%), nocturia (&lt;5%), hematuria (&ge;1%), pyuria (&ge;1%), urinary tract infection (&lt;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Leukocytosis (&lt;5%), anemia (&ge;1%), neutrophils abnormal (&ge;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Alkaline phosphatase increased (&ge;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia (5%), arthritis (&lt;5%), hyperkinesia (&lt;5%), muscle cramping (&lt;5%), myalgia (&lt;5%), paresthesia (&lt;5%), tremor (&lt;5%), weakness (&lt;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Eye abnormality (&lt;5%), vision abnormal (&lt;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Ear infection (&lt;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Sinusitis (8%), bronchitis (&lt;5%), dyspnea (&lt;5%), pharynx disorder (&lt;5%), rhinitis (&lt;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Viral infection (6%), abscess (&lt;5%), C-reactive protein increased (&lt;5%), diaphoresis (&lt;5%), flu-like syndrome (&lt;5%), erythrocyte sedimentation rate increased (&ge;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports (Limited to important or life-threatening): Anaphylaxis, intracranial hypertension (benign)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Oral inhaler (Pulmicort Flexhaler&reg;):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Syncope (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fever (&ge;3%), headache (&ge;3%), pain (&ge;3%), insomnia (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Bruising (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Dyspepsia (&ge;5%), nausea (2% to &ge;5%), abdominal pain (1% to 3%), taste perversion (1% to 3%), vomiting (1% to 3%), weight gain (1% to 3%), xerostomia (1% to 3%), gastroenteritis (viral; 2%), oral candidiasis (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia (&ge;5%), weakness (&ge;5%), back pain (&ge;3%), fracture (1% to 3%), hypertonia (1% to 3%), myalgia (1% to 3%), neck pain (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Otitis media (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Nasopharyngitis (9%), cough (&ge;5%), rhinitis (&ge;5%), respiratory infection (&ge;3%), sinusitis (&ge;3%), nasal congestion (3%), pharyngitis (3%), allergic rhinitis (2%), upper respiratory tract infection (viral; 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Infection (1% to 3%), voice alteration (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports (Limited to important or life-threatening): Aggressiveness, cataracts, depression, glaucoma, hypercorticism, hypersensitivity reactions (immediate and delayed [includes rash, contact dermatitis, angioedema, bronchospasm, urticaria]), hypocorticism, intraocular pressure increased, psychosis, wheezing (patients with severe milk allergy)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Oral tablets:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Central nervous system: Headache (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Mood swings (7%), fatigue (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Acne (2% to 5%), hirsutism (&lt;1% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Cortisol decreased (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (5%), upper abdominal pain (4%), flatulence (3%), abdominal distension (2%), constipation (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports (Limited to important or life-threatening): Anaphylaxis, intracranial hypertension (benign)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Suspension for nebulization:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Otitis media (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Respiratory infection (38%), rhinitis (11% to 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Chest pain (1% to &lt;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dysphonia (1% to &lt;3%), fatigue (1% to &lt;3%), mood swings (1% to &lt;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (4%), contact dermatitis (1% to &lt;3%), eczema (1% to &lt;3%), pruritus (1% to &lt;3%), purpura (1% to &lt;3%), pustular rash (1% to &lt;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Gastroenteritis (5%), diarrhea (4%), vomiting (4%), abdominal pain (3%), anorexia (1% to &lt;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Cervical lymphadenopathy (1% to &lt;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Fracture (1% to &lt;3%), hyperkinesia (1% to &lt;3%), myalgia (1% to &lt;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Conjunctivitis (4%), eye infection (1% to &lt;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Ear infection (5%), earache (1% to &lt;3%), otitis externa (1% to &lt;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Cough (8% to 9%), epistaxis (2% to 4%), stridor (1% to &lt;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Viral infection (4% to 5%), moniliasis (4% to 5%), allergic reaction (1% to &lt;3%), flu-like syndrome (1% to &lt;3%), herpes simplex (1% to &lt;3%), infection (1% to &lt;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports (Limited to important or life-threatening): Aggressiveness, avascular necrosis of the femoral head, bronchitis, cataracts, depression, glaucoma, growth suppression, hypercorticism, hypersensitivity reactions (immediate and delayed [includes angioedema, bronchospasm, urticaria]), hypocorticism, intraocular pressure increased, osteoporosis, psychosis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F7998649\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to budesonide or any component of the formulation; primary treatment of status asthmaticus, acute episodes of asthma; not for relief of acute bronchospasm",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): Moderate-to-severe bronchiectasis, pulmonary tuberculosis (active or quiescent), untreated respiratory infection (bacterial, fungal, or viral)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F7998650\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adrenal suppression: May cause hypercorticism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children, in patients receiving high doses for prolonged periods, or with concomitant CYP3A4 inhibitor use. HPA axis suppression may lead to adrenal crisis. Withdrawal and discontinuation of a corticosteroid should be done slowly and carefully. Particular care is required when patients are transferred from systemic corticosteroids to inhaled products or corticosteroids with lower systemic effect due to possible adrenal insufficiency or withdrawal from steroids, including an increase in allergic symptoms. Patients receiving &gt;20 mg per day of prednisone (or equivalent) may be most susceptible. Fatalities have occurred due to adrenal insufficiency in asthmatic patients during and after transfer from systemic corticosteroids to aerosol steroids; aerosol steroids do",
"     <b>",
"      not",
"     </b>",
"     provide the systemic steroid needed to treat patients having trauma, surgery, or infections. Do not use this product to transfer patients directly from oral corticosteroid therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bronchospasm: May occur with wheezing after inhalation; if this occurs stop steroid and treat with a fast-acting bronchodilator (eg, albuterol).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immunosuppression: Prolonged use of corticosteroids may also increase the incidence of secondary infection, mask acute infection (including fungal infections), prolong or exacerbate viral infections, or limit response to vaccines. Exposure to chickenpox should be avoided; corticosteroids should not be used to treat ocular herpes simplex. Corticosteroids should not be used for viral hepatitis. Close observation is required in patients with latent tuberculosis and/or TB reactivity; restrict use in active TB (only in conjunction with antituberculosis treatment).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Kaposi's sarcoma: Prolonged treatment with corticosteroids has been associated with the development of Kaposi's sarcoma (case reports); if noted, discontinuation of therapy should be considered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Local oral infections:",
"     <i>",
"      Candida albicans",
"     </i>",
"     infections may occur in the mouth and pharynx; rinsing (and spitting) with water after inhaler use may decrease risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myopathy: Acute myopathy has been reported with high-dose corticosteroids, usually in patients with neuromuscular transmission disorders; may involve ocular and/or respiratory muscles; monitor creatine kinase; recovery may be delayed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Psychiatric disturbances: Corticosteroid use may cause psychiatric disturbances, including depression, euphoria, insomnia, mood swings, and personality changes. Pre-existing psychiatric conditions may be exacerbated by corticosteroid use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Asthma: Supplemental steroids (oral or parenteral) may be needed during stress or severe asthma attacks. Not to be used in status asthmaticus or for the relief of acute bronchospasm.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with HF or hypertension; long-term use has been associated with fluid retention and hypertension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus; may alter glucose production/regulation leading to hyperglycemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal disease: Use with caution in patients with GI diseases (diverticulitis, peptic ulcer, ulcerative colitis) due to perforation risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment, including cirrhosis; long-term use has been associated with fluid retention. Increased oral bioavailability has been reported in patients with cirrhosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis; exacerbation of symptoms has occurred especially during initial treatment with corticosteroids.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myocardial infarction (MI): Use with caution following acute MI; corticosteroids have been associated with myocardial rupture.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ocular disease: Use with caution in patients with cataracts and/or glaucoma; increased intraocular pressure, open-angle glaucoma, and cataracts have occurred with prolonged use. Consider routine eye exams in chronic users.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Osteoporosis: Use with caution in patients with osteoporosis; high doses and/or long-term use of corticosteroids have been associated with increased bone loss and osteoporotic fractures.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; fluid retention may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorders: Use with caution in patients with a history of seizure disorder; seizures have been reported with adrenal crisis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid disease: Changes in thyroid status may necessitate dosage adjustments; metabolic clearance of corticosteroids increases in hyperthyroid patients and decreases in hypothyroid ones.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Because of the risk of adverse effects, systemic corticosteroids should be used cautiously in the elderly in the smallest possible effective dose for the shortest duration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Orally-inhaled corticosteroids may cause a reduction in growth velocity in pediatric patients (~1 centimeter per year [range 0.3-1.8 cm per year] and related to dose and duration of exposure). To minimize the systemic effects of orally-inhaled corticosteroids, each patient should be titrated to the lowest effective dose. Growth should be routinely monitored in pediatric patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lactose: Pulmicort Flexhaler&reg; contains lactose; very rare anaphylactic reactions have been reported in patients with severe milk protein allergy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Discontinuation of therapy: Withdraw systemic therapy with gradual tapering of dose. There have been reports of systemic corticosteroid withdrawal symptoms (eg, joint/muscle pain, lassitude, depression) when withdrawing oral inhalation therapy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F7998671\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F7998672\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphotericin B: Corticosteroids (Orally Inhaled) may enhance the hypokalemic effect of Amphotericin B.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the bioavailability of Corticosteroids (Oral). Management: Consider separating doses by 2 or more hours. Budesonide enteric coated tablets could dissolve prematurely if given with drugs that lower gastric acid, with unknown impact on budesonide therapeutic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents: Corticosteroids (Orally Inhaled) may diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Corticosteroids (Oral).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Budesonide (Systemic, Oral Inhalation). Management: Consider reducing the oral budesonide dose when used together with a CYP3A4 inhibitor.  This interaction is likely less severe with orally inhaled budesonide.  Monitor patients closely for signs/symptoms of corticosteroid excess.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of Budesonide (Systemic, Oral Inhalation). Management: Consider reducing the oral budesonide dose when used together with a CYP3A4 inhibitor.  This interaction is likely less severe with orally inhaled budesonide.  Monitor patients closely for signs/symptoms of corticosteroid excess.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of Corticosteroids (Orally Inhaled). Management: Monitor for signs and symptoms of adrenal suppression if inhaled budesonide or mometasone are coadministered with a strong CYP3A4 inhibitor.  Avoid combining inhaled fluticasone with any strong CYP3A4 inhibitor.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May increase the serum concentration of Budesonide (Systemic, Oral Inhalation).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Corticosteroids (Orally Inhaled) may enhance the hypokalemic effect of Loop Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May increase the serum concentration of Budesonide (Systemic, Oral Inhalation). Management: Concurrent use of telaprevir with budesonide is not recommended, unless the risk for excessive systemic corticosteroid effects is outweighed by the potential benefits.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Corticosteroids (Orally Inhaled) may enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F7998676\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Grapefruit juice may double systemic exposure of orally administered budesonide. Administration of capsules with a high-fat meal delays peak concentration, but does not alter the extent of absorption; administration of tablets with a high-fat meal decreases peak concentration (~27%). Management: Avoid grapefruit juice when using oral capsules or tablets.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Echinacea may diminish the therapeutic effect of budesonide. Management: Avoid echinacea.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F7998645\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (capsule, tablet)/B (inhalation) (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F7998646\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed with corticosteroids in animal reproduction studies. Some studies of pregnant women have shown an association between first trimester systemic corticosteroid use and oral clefts; adverse events in the fetus/neonate have been noted in case reports following large doses of systemic corticosteroids during pregnancy. Studies of pregnant women using inhaled budesonide have not demonstrated an increased risk of abnormalities. Inhaled corticosteroids are recommended for the treatment of asthma during pregnancy; budesonide is preferred (ACOG, 2008; NAEPP, 2005)",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F7998648\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F8082655\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Following use of the powder for oral inhalation, ~0.3% to 1% of the maternal dose was found in breast milk. The maximum concentration appeared within 45 minutes of dosing. Plasma budesonide levels obtained from infants ~90 minutes after breast-feeding (~140 minutes after maternal dose) were below the limit of quantification. Concentrations of budesonide in breast milk are expected to be higher following administration of oral capsules/tablets than after an inhaled dose. The use of inhaled corticosteroids is not considered a contraindication to breast-feeding (NAEPP, 2005).",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F7998728\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral capsules, tablets: Avoid grapefruit juice.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F7998747\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Aerosol powder",
"     </b>",
"     (Pulmicort Flexhaler Inhalation)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     90 mcg/ACT (1): $143.87",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     180 mcg/ACT (1): $192.65",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsule, 24-hour",
"     </b>",
"     (Budesonide ER Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3 mg (100): $1711.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsule, 24-hour",
"     </b>",
"     (Entocort EC Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3 mg (100): $2510.75",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Budesonide Inhalation)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.25 mg/2 mL (2 mL): $9.41",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5 mg/2 mL (2 mL): $11.08",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Pulmicort Inhalation)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.25 mg/2 mL (2 mL): $10.46",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5 mg/2 mL (2 mL): $12.31",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg/2 mL (2 mL): $24.62",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 24-hour",
"     </b>",
"     (Uceris Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     9 mg (30): $1482.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F7998731\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor growth in pediatric patients; blood pressure, serum glucose, weight with high-dose or long-term oral use; signs and symptoms of hypercorticism or adrenal suppression",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Asthma: FEV",
"     <sub>",
"      1",
"     </sub>",
"     , peak flow, and/or other pulmonary function tests",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F10961959\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Aeronide (TH);",
"     </li>",
"     <li>",
"      Aquacort (DE);",
"     </li>",
"     <li>",
"      B Cort (CO);",
"     </li>",
"     <li>",
"      Bronex (PH);",
"     </li>",
"     <li>",
"      Budair (MY);",
"     </li>",
"     <li>",
"      Budecort DP (MY);",
"     </li>",
"     <li>",
"      Budenofalk (DE, HK, KP, PH, SG);",
"     </li>",
"     <li>",
"      Budeson (AR);",
"     </li>",
"     <li>",
"      Budeson Aqua (AR);",
"     </li>",
"     <li>",
"      BudeSpray (TH);",
"     </li>",
"     <li>",
"      Budiair (KP);",
"     </li>",
"     <li>",
"      Budicort Respules (IL);",
"     </li>",
"     <li>",
"      Bunase (TH);",
"     </li>",
"     <li>",
"      Clebudan (CN);",
"     </li>",
"     <li>",
"      Cycortide (HK);",
"     </li>",
"     <li>",
"      Denecort (PH);",
"     </li>",
"     <li>",
"      Duasma (TW);",
"     </li>",
"     <li>",
"      Eltair (MY);",
"     </li>",
"     <li>",
"      Entocort (AR, AT, BE, BR, CH, CZ, DK, FI, FR, GB, HK, IE, IL, IT, KP, NL, NO, PL, PT, SE, TR);",
"     </li>",
"     <li>",
"      Giona Easyhaler (MY, SG, TH);",
"     </li>",
"     <li>",
"      Inflammide (PE);",
"     </li>",
"     <li>",
"      Miflonid (CZ);",
"     </li>",
"     <li>",
"      Miflonide (BE, DE, IL, IT, NZ, PT);",
"     </li>",
"     <li>",
"      Neumocort (PY);",
"     </li>",
"     <li>",
"      Novopulmon (DE, FR);",
"     </li>",
"     <li>",
"      Pulmicon Susp for Nebulizer (KP);",
"     </li>",
"     <li>",
"      Pulmicort (AT, BE, BG, BR, CH, CL, CN, CO, CR, CZ, DE, DK, DO, EE, FI, FR, GB, GR, GT, HN, ID, IN, NI, NL, NO, PA, PK, PL, PT, RU, SE, SV, TR, TW, UY, VE);",
"     </li>",
"     <li>",
"      Pulmicort Nasal Turbohaler (CL, KE, MU, NG);",
"     </li>",
"     <li>",
"      Pulmicort Turbuhaler (KE, MU, NG);",
"     </li>",
"     <li>",
"      Rafton (FR);",
"     </li>",
"     <li>",
"      Rhinocort Aqua (HK);",
"     </li>",
"     <li>",
"      Rhinoside (GR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F7998679\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Controls the rate of protein synthesis; depresses the migration of polymorphonuclear leukocytes, fibroblasts; reverses capillary permeability and lysosomal stabilization at the cellular level to prevent or control inflammation. Has potent glucocorticoid activity and weak mineralocorticoid activity.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F7998681\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Nebulization: 2-8 days; Inhalation: 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peak effect: Nebulization: 4-6 weeks; Inhalation: 1-2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: 2.2-3.9 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 85% to 90%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via CYP3A4 to two metabolites: 16 alpha-hydroxyprednisolone and 6 beta-hydroxybudesonide; minor activity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Limited by high first-pass effect; Capsule: 9% to 21%; Nebulization: 6%; Inhalation: 6% to 13%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 2-3.6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: Capsule: 0.5-10 hours (variable in Crohn's disease); Nebulization: 10-30 minutes; Inhalation: 1-2 hours; Tablet: 7.4-19.2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (60%) and feces as metabolites",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Asthma In Pregnancy,&rdquo; ACOG Practice Bulletin No. 90. American College of Obstetricians and Gynecologists,",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2008, 111(2 Pt 1):457-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/39/10873/abstract-text/18238988/pubmed\" id=\"18238988\" target=\"_blank\">",
"        18238988",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Expert Panel Report 3, &ldquo;Guidelines for the Diagnosis and Management of Asthma,&rdquo;",
"      <i>",
"       Clinical Practice Guidelines",
"      </i>",
"      , National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 08-4051, prepublication 2007. Available at",
"      <a href=\"file://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm\" target=\"_blank\">",
"       file://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      <i>",
"       Global Strategy for Asthma Management and Prevention",
"      </i>",
"      , Global Initiative for Asthma (GINA) 2011. Available at file://www.ginasthma.org",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lichtenstein GR, Hanauer SB, and Sandborn WJ, &ldquo;Management of Crohn's Disease in Adults,&rdquo;",
"      <i>",
"       Am J Gastroenterol",
"      </i>",
"      , 2009, 104(2):465-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/39/10873/abstract-text/19174807/pubmed\" id=\"19174807\" target=\"_blank\">",
"        19174807",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lougheed MD, Lemi&egrave;re C, Dell SD, et al, &ldquo;Canadian Thoracic Society Asthma Management Continuum - 2010 Consensus Summary for Children Six Years of Age and Over, and Adults,&rdquo;",
"      <i>",
"       Can Respir J",
"      </i>",
"      , 2010, 17(1):15-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/39/10873/abstract-text/20186367/pubmed\" id=\"20186367\" target=\"_blank\">",
"        20186367",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McGee S and Hirschmann J, &ldquo;Use of Corticosteroids in Treating Infectious Diseases,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 2008, 168(10):1034-46.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/39/10873/abstract-text/18504331/pubmed\" id=\"18504331\" target=\"_blank\">",
"        18504331",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      NAEPP Working Group Report on &ldquo;Managing Asthma During Pregnancy: Recommendations for Pharmacologic Treatment,&rdquo; National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 05-5236, March 2005. Available at",
"      <a href=\"file://www.nhlbi.nih.gov/health/prof/lung/asthma/astpreg/astpreg_full.pdf\" target=\"_blank\">",
"       file://www.nhlbi.nih.gov/health/prof/lung/asthma/astpreg/astpreg_full.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ostensen M, &ldquo;Optimisation of Antirheumatic Drug Treatment in Pregnancy,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1994, 27(6):486-503.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/39/10873/abstract-text/7882637/pubmed\" id=\"7882637\" target=\"_blank\">",
"        7882637",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pradat P, Robert-Gnansia E, Di Tanna GL, et al, &ldquo;First Trimester Exposure to Corticosteroids and Oral Clefts,&rdquo;",
"      <i>",
"       Birth Defects Res A Clin Mol Teratol",
"      </i>",
"      , 2003, 67(12):968-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/39/10873/abstract-text/14745915/pubmed\" id=\"14745915\" target=\"_blank\">",
"        14745915",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Todd GR, Acerini CL, Buck JJ, et al, \"Acute Adrenal Crisis in Asthmatics Treated With High-Dose Fluticasone Propionate,\"",
"      <i>",
"       Eur Respir J",
"      </i>",
"      , 2002, 19(6):1207-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/39/10873/abstract-text/12108877/pubmed\" id=\"12108877\" target=\"_blank\">",
"        12108877",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Todd GR, Acerini CL, Ross-Russell R, et al, \"Survey of Adrenal Crisis Associated With Inhaled Corticosteroids in the United Kingdom,\"",
"      <i>",
"       Arch Dis Child",
"      </i>",
"      , 2002, 87(6):457-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/39/10873/abstract-text/12456538/pubmed\" id=\"12456538\" target=\"_blank\">",
"        12456538",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9036 Version 48.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-75F91836D7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_39_10873=[""].join("\n");
var outline_f10_39_10873=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7998594\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7998595\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7998598\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7998725\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7998724\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7998726\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14311016\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7998727\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7998744\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7998745\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7998596\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7998729\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7998644\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7998653\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7998649\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7998650\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7998671\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7998672\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7998676\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7998645\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7998646\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7998648\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082655\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7998728\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7998747\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7998731\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10961959\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7998679\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7998681\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9036\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9036|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?18/55/19317?source=related_link\">",
"      Budesonide (nasal): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?7/59/8116?source=related_link\">",
"      Budesonide (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/35/42547?source=related_link\">",
"      Budesonide (nasal): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?24/45/25303?source=related_link\">",
"      Budesonide (systemic therapy and oral inhalation): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/36/21064?source=related_link\">",
"      Budesonide (systemic therapy and oral inhalation): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_39_10874="Natural history and therapy of myocarditis in adults";
var content_f10_39_10874=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Natural history and therapy of myocarditis in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/39/10874/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/39/10874/contributors\">",
"     Leslie T Cooper, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/39/10874/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/39/10874/contributors\">",
"     William J McKenna, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/39/10874/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/39/10874/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/39/10874/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 11, 2009.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myocarditis refers to inflammation of the heart muscle that may be identified by clinical or histopathologic criteria. The clinical manifestations of this disorder vary greatly from asymptomatic changes on an electrocardiogram to fulminant heart failure (HF); arrhythmias, heart block, and a syndrome resembling acute myocardial infarction (MI) may also be present. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/16/26889?source=see_link\">",
"     \"Clinical manifestations and diagnosis of myocarditis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Extracardiac signs and symptoms may identify infectious and toxic agents or autoimmune diseases affecting the heart and resulting in a myocarditis. For example, a viral prodrome of fever, myalgias, and muscle tenderness may precede viral myocarditis, while a delayed hypersensitivity reaction may be first apparent from a cutaneous rash, eosinophilia, and elevated liver enzyme levels.",
"   </p>",
"   <p>",
"    Treatment of myocarditis consists of both specific therapy aimed at the cause of the myocarditis and nonspecific therapy aimed at the clinical manifestations such as HF and arrhythmias. Before discussing these issues, it is useful to review what is known about the natural history of this disorder. The etiology, incidence, pathogenesis, clinical manifestations, and diagnosis of myocarditis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/28/22986?source=see_link\">",
"     \"Etiology and pathogenesis of myocarditis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/16/26889?source=see_link\">",
"     \"Clinical manifestations and diagnosis of myocarditis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A significant minority of patients with pericarditis also have myocarditis, a disorder called myopericarditis. Myopericarditis, including vaccinia-associated disease (myocarditis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pericarditis), is discussed separately (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/60/41927?source=see_link\">",
"     \"Myopericarditis\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of myocarditis in community based populations is not known with any accuracy because there is no widely available noninvasive diagnostic test to confirm the diagnosis. However, seroepidemiologic studies suggest that the majority of cases of Coxsackie B virus infection are subclinical and have a benign course [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10874/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In hospital or clinic based referral populations, the natural history of myocarditis varies with the underlying cause and the presenting symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10874/abstract/2\">",
"     2",
"    </a>",
"    ]. In the majority of patients who develop inflammation as evidenced by electrocardiographic (ECG) changes, the inflammatory process is apparently self-limited without short-term, overt sequelae. More severe ECG changes such as bundle branch block, high degree AV block, and Q waves are associated with worse long term clinical outcomes. A minority of initially asymptomatic patients, however, develop HF, serious arrhythmias, disturbances of conduction, or even circulatory collapse. Rarely, postviral myocarditis may be fatal due to myocardial failure or sudden, unexpected death [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10874/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, most patients with symptomatic post-viral or lymphocytic myocarditis present with HF and dilated cardiomyopathy (DCM). However, subtle signs and symptoms of cardiac involvement may be overshadowed by systemic manifestations of the viral infection. As an example, in the US Myocarditis Treatment Trial, 89 percent of subjects reported a syndrome consistent with a viral prodrome [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10874/abstract/4\">",
"     4",
"    </a>",
"    ]. Although only a small fraction of patients with lymphocytic myocarditis present with ventricular arrhythmias, the percentage of patients with idiopathic ventricular tachycardia who have myocarditis may be as high as 33 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10874/abstract/5\">",
"     5",
"    </a>",
"    ]. Myocarditis may also cause some cases of atrial fibrillation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10874/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The multicenter IMAC trial, which evaluated the role of intravenous immune globulin (IVIG), enrolled patients with a decreased left ventricular ejection fraction (LVEF) and HF symptoms for six months; however, only 11 percent of patients had \"Dallas criteria\" positive myocarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10874/abstract/7\">",
"     7",
"    </a>",
"    ]. Most patients were treated with ACE inhibitors and beta blockers. The average LVEF increased 14 percent, regardless of IVIG treatment, demonstrating that most patients with acute DCM will have an improvement in left ventricular (LV) function with nonspecific HF therapy.",
"   </p>",
"   <p>",
"    The patients with myocarditis presenting with a DCM from the Myocarditis Treatment Trial had early remodeling of the LV with chamber dilation and the development of a more spherical cavity [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10874/abstract/8\">",
"     8",
"    </a>",
"    ]. Over 50 percent of these patients demonstrated reversibility of the remodeling process with a reduction in LV volume and restoration of a more elliptical-shaped chamber, which was associated with improvement in LVEF.",
"   </p>",
"   <p>",
"    In a significant minority of patients with acute myocarditis, decreased cardiac reserve, arrhythmias, or disturbances of conduction may persist for months to years; this can be due to residual scar tissue, persistent active myocarditis or occasionally persistent viral infection [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10874/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. In a review of 1230 patients with initially unexplained cardiomyopathy, 9 percent had myocarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10874/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Role of autoantibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is suggestive evidence that some cases of myocarditis lead to DCM because of ongoing autoimmune reaction to myocardial proteins (",
"    <a class=\"graphic graphic_figure graphicRef74290 \" href=\"UTD.htm?2/13/2270\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10874/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. As an example, the presence of anti-alpha myosin autoantibodies may be associated with a worse prognosis in chronic cardiomyopathy, as manifested by a lower likelihood of improvement in LV systolic and diastolic function compared to patients without these antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10874/abstract/13\">",
"     13",
"    </a>",
"    ]. Patients with antibodies had no improvement in LVEF at six months compared to a 9 percent absolute increase in those without antibodies. Similarly, the presence of anti-heart antibodies in relatives of patients with idiopathic DCM predicts future left ventricular dilation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10874/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, in patients with acute cardiomyopathy, higher titers of anti-cardiac IgG were associated with better left ventricular function in the Myocarditis Treatment Trial [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10874/abstract/4\">",
"     4",
"    </a>",
"    ]. This observation suggests that the acute immune response to viral infection usually serves to eliminate the pathogen and improve heart function. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/28/22986?source=see_link&amp;anchor=H22#H22\">",
"     \"Etiology and pathogenesis of myocarditis\", section on 'Autoimmune mechanisms'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The long-term prognosis of most relatively mild cases of myocarditis is not known since the primary diagnostic tool &mdash; endomyocardial biopsy &mdash; tends to be applied only to patients with major clinical manifestations such as refractory HF or life-threatening arrhythmias.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Lymphocytic, presumably viral myocarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis of myocarditis is dependent upon both the cause and severity of the disease. Lymphocytic myocarditis, for example, has a variable course:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Some patients have subclinical disease",
"     </li>",
"     <li>",
"      Some have indolent disease that progresses to DCM",
"     </li>",
"     <li>",
"      Others present with fulminant disease that may be fatal or may fully resolve after acute hemodynamic support",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In one report of 27 patients (mean age 47) with myocardial biopsy-proven definite or borderline myocarditis, the five-year survival was 56 percent, similar to that in a comparison cohort of patients with idiopathic DCM without myocarditis (",
"    <a class=\"graphic graphic_figure graphicRef64625 \" href=\"UTD.htm?5/5/5213\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10874/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is uncertain what data at presentation can predict outcome in acute viral myocarditis. In a series of 109 cases with Dallas criteria positive (active or borderline) myocarditis, findings at presentation that were predictive of subsequent death or transplantation were syncope (relative risk 8.5), bundle branch block (relative risk 2.9), and an LVEF &lt;40 percent (relative risk 2.9) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10874/abstract/16\">",
"     16",
"    </a>",
"    ]. Although borderline histology was protective, this was not seen in other series [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10874/abstract/15,17\">",
"     15,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another adverse prognostic factor is the development of secondary pulmonary hypertension. This was illustrated in a prospective study of 1134 patients with a new cardiomyopathy who underwent right heart catheterization and endomyocardial biopsy and were followed for 4.4 years [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10874/abstract/18\">",
"     18",
"    </a>",
"    ]. In a multivariate model, mean pulmonary artery pressure was the most important hemodynamic predictor of death, especially in the 93 patients (8.3 percent) with a diagnosis of myocarditis. For each 5 mmHg increase in baseline mean pulmonary artery pressure, the mortality in those with and without myocarditis increased with a relative hazard of 1.85 and 1.23, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Fulminant myocarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who present with fulminant myocarditis, although more severely ill, may be more likely to fully recover than those with acute myocarditis, if they survive the acute phase of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10874/abstract/17,19\">",
"     17,19",
"    </a>",
"    ]. This hypothesis was examined in a study of 147 patients with biopsy proven myocarditis, 15 of whom had fulminant myocarditis based upon presenting clinical features, which included severe hemodynamic compromise, rapid onset of symptoms, and fever [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10874/abstract/17\">",
"     17",
"    </a>",
"    ]. After an 11 year follow-up, survival free of transplant was significantly better in those with fulminant myocarditis (93 versus 45 percent for acute or borderline myocarditis) (",
"    <a class=\"graphic graphic_figure graphicRef59375 \" href=\"UTD.htm?39/42/40621\">",
"     figure 3",
"    </a>",
"    ). After adjusting for age, hemodynamic variables, and histopathologic variables, fulminant myocarditis was an independent predictor of survival. The long-term outcome in children with fulminant lymphocytic myocarditis is also good if they can be supported through the acute illness [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10874/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Persistence of viral genome",
"    </span>",
"    &nbsp;&mdash;&nbsp;An important predictor of outcome in patients with viral myocarditis may be the presence or absence of persistence of the viral genome in the myocardium. This was suggested in a consecutive series of 172 patients with proven viral infection in endomyocardial biopsies; the patients had a relatively long duration of symptoms (5.1 months) before the initial endomyocardial biopsy and were already on a reasonable heart failure regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10874/abstract/21\">",
"     21",
"    </a>",
"    ]. Among the 151 patients with a single infection, follow-up biopsy at a median of 6.8 months revealed spontaneous clearance of the viral genome in 55 (36 percent). These patients had a significant increase in LVEF (from 50 to 58 percent), while those with persisting viral genomes had a significant reduction in LVEF (from 54 to 51 percent).",
"   </p>",
"   <p>",
"    However, other case series in which parvovirus B19 was the most frequent pathogen have not demonstrated an effect of viral genome on the risk of death or heart transplantation, raising a possibility that viral genomes may sometimes refect latent and not active viral infection [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10874/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Persistence of viral genome may also identify patients particularly unlikely to respond to immunosuppressive therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10874/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Immunosuppressive therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Although these data suggest that persistence of viral genome may predict a gradual deterioration of left ventricular function in chronic dilated cardiomyopathy, a clinical role for endomyocardial biopsy in the management of such patients will depend upon more definitive evidence of effective treatment of viral cardiomyopathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Role of serologic markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although clinical parameters are only partly predictive of outcome, serologic markers, particularly soluble Fas ligand (FasL) and interleukin (IL)-10 may be useful in acute, severe myocarditis. Fas (CD95), a member of the tumor necrosis factor receptor family, is expressed following B-cell activation. Binding of Fas with its natural ligand (FasL, which is expressed on activated T-cells) triggers apoptotic cell death. As a result, Fas regulates clonal expansion of autoreactive B-cells.",
"   </p>",
"   <p>",
"    In one series, serum concentrations of soluble Fas and FasL were significantly higher in patients with acute myocarditis compared to normals or patients with an old MI [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10874/abstract/24\">",
"     24",
"    </a>",
"    ]. Among the patients with myocarditis, Fas and FasL concentrations were significantly higher in those who died during hospitalization compared to those discharged from the hospital after recovery.",
"   </p>",
"   <p>",
"    Further support for the role of Fas comes from a study of 20 patients with recent-onset idiopathic dilated cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10874/abstract/25\">",
"     25",
"    </a>",
"    ]. The patients in the highest tertile of Fas expression in the myocardium had minimal improvement in LVEF at six months compared to those in the intermediate and lowest tertiles (3 versus 10 and 21 percent, respectively).",
"   </p>",
"   <p>",
"    A higher serum IL-10 concentration on admission may be predictive of cardiogenic shock and death in patients with fulminant myocarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10874/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Giant cell myocarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Idiopathic giant cell myocarditis (GCM) is a rare and frequently fatal type of myocarditis. The pathogenesis of this disorder is not known. In an animal model, a disorder similar to GCM was induced by immunization with cardiac myosin [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10874/abstract/27\">",
"     27",
"    </a>",
"    ]. However, antimyosin antibodies are frequently found in patients with myocarditis and are not limited to those with GCM. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/28/22986?source=see_link\">",
"     \"Etiology and pathogenesis of myocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In our series of 63 patients with GCM, the presenting symptoms were HF (75 percent), ventricular arrhythmias (14 percent), and heart block (5 percent). Initial symptoms resembling an acute MI were present in 6 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10874/abstract/28\">",
"     28",
"    </a>",
"    ]. The rate of death or cardiac transplant was 89 percent and the median survival from onset of symptoms was 5.5 months. This represents a significantly worse prognosis compared to lymphocytic or viral myocarditis. In the Myocarditis Treatment Trial, approximately 50 percent of such patients are alive without cardiac transplant at five years [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10874/abstract/4\">",
"     4",
"    </a>",
"    ]. Potential therapies for this disorder are described below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Recent-onset idiopathic DCM",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis may be relatively good in patients with recent-onset idiopathic DCM (&le;6 months). In a randomized trial of 62 such patients, some of whom had proven myocarditis, the LVEF rose from 25 percent at baseline to 42 percent at one year, 36 percent had a normal LVEF, and the transplant-free survival at one and two years was 92 and 88 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10874/abstract/7\">",
"     7",
"    </a>",
"    ]. Administration of intravenous immune globulin had no apparent effect.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SPECIFIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of causes (primarily infectious) of myocarditis for which there is specific therapy, such as Mycoplasma or Lyme disease (Borrelia burgdorferi) (",
"    <a class=\"graphic graphic_table graphicRef72399 \" href=\"UTD.htm?13/51/14139\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10874/abstract/1\">",
"     1",
"    </a>",
"    ]. It must be pointed out, however, that whereas specific therapy may be available for these infections, it has not been established that the myocarditic process itself will be favorably affected. Similar considerations apply to autoimmune disorders such as lupus myocarditis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/59/22456?source=see_link&amp;anchor=H11#H11\">",
"     \"Non-coronary cardiac manifestations of systemic lupus erythematosus in adults\", section on 'Myocarditis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Lymphocytic myocarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Viral infection is the most common identified cause of lymphocytic myocarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10874/abstract/1,29\">",
"     1,29",
"    </a>",
"    ]. From the 1950s through the 1980s experimental and seroepidemiologic studies linked enteroviruses, particularly Coxsackie B species, with myocarditis. In the late 1980s molecular techniques, such as polymerase chain reaction (PCR), identified viral genomes in the heart tissue of patients with acute myocarditis and DCM. The spectrum of viruses associated with myocarditis has broadened as PCR has been used to identify many different viral genomes in heart specimens. Currently the most common genomes identified are parvovirus B19 and human herpes virus 6. Enterovirus still causes myocarditis in small regional outbreaks. Heart biopsy for viral genome analysis is rarely performed in many regions of the world, and thus the prevalence of viral myocarditis in much of Africa, Asia, the Middle East, and South America is uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Antiviral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antiviral therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    or interferon alfa reduces the severity of myocardial lesions and mortality in experimental murine myocarditis due to Coxsackievirus B3 [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10874/abstract/30-33\">",
"     30-33",
"    </a>",
"    ]. However, this beneficial effect is seen only if therapy is started prior to inoculation or soon thereafter. The applicability of these findings to humans is therefore uncertain, since patients with viral myocarditis are usually not seen in the earlier stages. Nevertheless, antiviral therapy may be considered in acute, fulminant myocarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10874/abstract/34\">",
"     34",
"    </a>",
"    ], in institutional outbreaks (eg, in neonates), and in laboratory-acquired cases.",
"   </p>",
"   <p>",
"    Antiviral therapy with interferon beta may also be beneficial for patients with chronic DCM and evidence of viral genome in endomyocardial biopsy specimens by the polymerase chain reaction (PCR). In a series of 22 patients with persistent LV dysfunction, symptomatic HF, and enteroviral or adenoviral persistence in the myocardium by PCR, 18 x 10(6) IU per week of beta interferon was given subcutaneously for 24 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10874/abstract/35\">",
"     35",
"    </a>",
"    ]. Viral genome by PCR was eradicated in all patients after antiviral therapy. Viral clearance was paralleled by a significant decrease in LV size and a significant increase in LV function.",
"   </p>",
"   <p>",
"    A randomized, placebo-controlled trial (Beta Interferon for Chronic Cardiomyopathy, BICC) is currently underway to confirm these findings. Alpha interferon may offer similar benefits, but this agent has not been systematically studied [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10874/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Immunosuppressive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because inflammation may persist in the myocardium after clearance of the initial pathogen, triggered by endogenous autoantigens, it has been postulated that immunosuppressive therapy might be effective in select cases of myocarditis. However, both corticosteroids and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    exacerbate acute murine viral myocarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10874/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. The effect of immunosuppression varies with the mouse strain, virus, and timing of treatment. In one study",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil inhibited the development of Coxsackie B virus myocarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10874/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of initial therapeutic studies in humans, mostly uncontrolled, have suggested clinical benefit from immunosuppressive therapy with corticosteroids,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10874/abstract/40-42\">",
"     40-42",
"    </a>",
"    ]. However, evaluation of true effectiveness is difficult in myocarditis because of the high rate of spontaneous recovery [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10874/abstract/7,43\">",
"     7,43",
"    </a>",
"    ]. Furthermore, two small randomized, controlled trials of immunomodulatory agents",
"    <strong>",
"     failed",
"    </strong>",
"    to demonstrate any therapeutic effect in biopsy-proven active acute myocarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10874/abstract/4,44\">",
"     4,44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the larger trial (Myocarditis Treatment Trial), 111 patients with a histopathologic diagnosis of myocarditis and an LVEF of less than 45 percent were randomly assigned to receive conventional therapy alone or immunosuppression with either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      for 28 weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?10/39/10874/abstract/4\">",
"       4",
"      </a>",
"      ]. In all patients, the LVEF improved from 25 to 34 percent and the mortality rate was 20 percent at one year and 56 percent at 4.3 years. There was no difference in outcome in the two treatment groups. A more robust inflammatory response was associated with less severe disease and a greater improvement in cardiac function.",
"     </li>",
"     <li>",
"      In contrast to acute myocarditis, patients with evidence of chronic inflammation may respond to immunomodulatory therapy. The second trial consisted of 84 patients with a DCM of greater than six months duration who had evidence of chronic inflammation on biopsy; the patients were randomly assigned to receive either immunosuppression or placebo for three months and then were followed for two years [",
"      <a class=\"abstract\" href=\"UTD.htm?10/39/10874/abstract/44\">",
"       44",
"      </a>",
"      ]. There was no difference in the primary end point (death, heart transplantation, or hospital readmission) at two years (23 versus 21 percent for placebo). However, patients treated with immunosuppressive therapy had a significantly greater improvement in LVEF and clinical status.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A randomized trial compared outcomes with immunosuppressive treatment as compared to placebo in a chronic stable DCM population [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10874/abstract/45\">",
"     45",
"    </a>",
"    ]. Of 512 patients with LVEF &le;45 percent who were screened with endomyocardial biopsy, 85 subjects without viral genomes by PCR were assigned to either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    or placebo for six months. The immunohistological criteria were the presence of &gt;14 CD45 or &gt;2 CD3 positive T cells per high power field. The presence of circulating anti-heart antibodies were not required for enrollment. The LVEF improved by &gt;10 percent in 38 of 43 patients treated with immunosuppression, compared to none of the patients treated with placebo. Indeed the placebo-treated patients' mean LVEF declined from 27.8 percent to 19.7 percent after six months. Clinical improvement in the immunosuppression treated subjects was reflected in significantly lower average NYHA functional class (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"     table 2",
"    </a>",
"    ) at six months.",
"   </p>",
"   <p>",
"    There are several possible explanations for the lack of effect on event-free survival in these trials of acute cardiomyopathy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most patients with acute cardiomyopathy improve with standard heart failure care. As a result, an additive effect of immunosuppressive treatment is not detectable, because of this improvement in the control arms.",
"     </li>",
"     <li>",
"      The use of Dallas criteria for the diagnosis of myocarditis may not have identified the patients who would benefit from immunosuppression [",
"      <a class=\"abstract\" href=\"UTD.htm?10/39/10874/abstract/46\">",
"       46",
"      </a>",
"      ]. Markers of immune activation rather than cellular infiltrates (Dallas criteria) seem to identify a patient population in which there may be benefit to immunosuppression [",
"      <a class=\"abstract\" href=\"UTD.htm?10/39/10874/abstract/44,47\">",
"       44,47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The findings do not apply to all patients with myocarditis, such as children, those with cardiogenic shock, or those presenting with primary arrhythmias.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is possible that further studies may identify a subset of patients with acute myocarditis responsive to such a regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10874/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. A nonrandomized study evaluated 41 patients with progressive HF for six months or more who were unresponsive to standard therapy and who had active lymphocytic myocarditis on biopsy. All 41 were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10874/abstract/23\">",
"     23",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Twenty patients were nonresponders (no improvement in LVEF); 17 had viral genomes in biopsy specimens and none had cardiac autoantibodies.",
"     </li>",
"     <li>",
"      Twenty-one patients were responders (rapid improvement in LVEF from 26 to 47 percent) with evidence of healed myocarditis on repeat myocardial biopsy; 19 had cardiac autoantibodies (identified by indirect immunofluorescence) and only three had viral genomes in biopsy specimens (all hepatitis C virus).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although it is possible that the presence of cardiac autoantibodies simply identified patients who had spontaneous improvement, other data cited above suggested that such patients may have a worse prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10874/abstract/13\">",
"     13",
"    </a>",
"    ]. Further support for the pathogenicity of autoantibodies, perhaps particularly those of the IgG3 subclass, comes from clinical improvement following immunoadsorption against columns that remove these antibodies in patients with idiopathic DCM [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10874/abstract/50-53\">",
"     50-53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Limited data are available on the use of immunosuppressive therapy of lymphocytic myocarditis in the setting of unexplained ventricular arrhythmias. In one study, 17 of 65 patients had unexplained ventricular arrhythmias in the apparent absence of structural heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10874/abstract/54\">",
"     54",
"    </a>",
"    ]. Twelve of these patients underwent endomyocardial biopsy and six had evidence of lymphocytic myocarditis. These six patients were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ; none had recurrent spontaneous arrhythmias and none had ventricular arrhythmias that could be induced by electrophysiologic stimulation despite cessation of antiarrhythmic medications. Since data are limited, the indications for and value of detection of myocarditis in this setting are controversial. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/26/7592?source=see_link&amp;anchor=H17#H17\">",
"     \"Endomyocardial biopsy\", section on 'Unexplained arrhythmias'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     IVIG",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous immunoglobulin (IVIG) has antiviral and immunomodulatory effects, suggesting that it may play a role in the treatment of viral myocarditis. However, studies in patients with proven viral myocarditis are lacking and a systematic review concluded that there are insufficient data from methodologically strong studies to recommend routine IVIG therapy in patients with acute myocarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10874/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    IVIG has also been used in patients with recent-onset DCM with no proven benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10874/abstract/7\">",
"     7",
"    </a>",
"    ]. In contrast, in a randomized, placebo-controlled trial in chronic DCM, IVIG significantly improved LVEF [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10874/abstract/56\">",
"     56",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Acute, idiopathic DCM'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     NSAIDs",
"    </span>",
"    &nbsp;&mdash;&nbsp;In animal models of myocarditis, nonsteroidal antiinflammatory drugs (NSAIDs) are",
"    <strong>",
"     not effective",
"    </strong>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10874/abstract/57-59\">",
"     57-59",
"    </a>",
"    ]. To the contrary, they may actually enhance the myocarditic process and increase mortality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Acute, idiopathic DCM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although viral infection is the most common identified cause for myocarditis presenting as dilated cardiomyopathy (DCM), investigation does not reveal an etiology in approximately 50 percent of patients. The majority of these cases probably result from either an occult infection, an autoimmune process, or the early stages of a genetically determined myocardial disease. The possible role of autoimmunity has led to evaluation of the effectiveness of IVIG.",
"   </p>",
"   <p>",
"    A randomized, controlled trial of 62 patients with recent-onset DCM (&le;6 months) or myocarditis found that the improvement in LV function was the same with IVIG (1",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day for two days) and placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10874/abstract/7\">",
"     7",
"    </a>",
"    ]. At one year, both groups of patients did well as the LVEF rose from 25 percent at baseline to 42 percent. 36 percent had a normal LVEF, and the transplant-free survival at one and two years was 92 and 88 percent.",
"   </p>",
"   <p>",
"    However, IVIG appears to benefit children with recent-onset idiopathic myocarditis and DCM [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10874/abstract/20,60\">",
"     20,60",
"    </a>",
"    ]. An improvement in function and survival compared with historical controls following IVIG was also suggested in an initial report of 10 adults with HF due to a DCM of less than six months duration [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10874/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Giant cell myocarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to the variable clinical course of DCM due to lymphocytic myocarditis, the clinical course in giant cell myocarditis (GCM) is usually characterized by acute or fulminant deterioration in LVEF despite standard HF treatment, frequent ventricular arrhythmias, and heart block. In one study of 63 patients the rate of death or cardiac transplantation was 89 percent, and median survival was only 5.5 months from the onset of symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10874/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Myocardial inflammation appears mediated by T cells and giant cells and therapy directed at T cells may therefore be of benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10874/abstract/62\">",
"     62",
"    </a>",
"    ]. In case reports, two patients responded favorably to cytolytic therapy with muromonab-CD3&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10874/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unlike DCM and lymphocytic myocarditis, patients with GCM treated with certain immunosuppressive regimes may have a significantly improved survival compared to patients who do not receive immunosuppressive treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10874/abstract/28,64\">",
"     28,64",
"    </a>",
"    ]. Among 22 patients treated with immunosuppressive medications, the average transplant-free survival was 13 months compared with only three months among 30 patients who did not receive therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10874/abstract/28\">",
"     28",
"    </a>",
"    ]. These results were confirmed in a prospective study of 11 patients with GCM who were treated with one year of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and corticosteroids; nine patients also received 7 to 10 days of muromonab-CD3&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10874/abstract/64\">",
"     64",
"    </a>",
"    ]. Among the 11 patients there was only one death and two transplantations during one year of follow up.",
"   </p>",
"   <p>",
"    Transplantation is an effective therapy for GCM. Among 34 patients who underwent transplantation for this disease, recurrence was documented in nine after an average follow-up of three years [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10874/abstract/65\">",
"     65",
"    </a>",
"    ]. Post transplantation survival was 71 percent at three years despite a 25 percent rate of histologic recurrence on post-transplant endomyocardial biopsy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Eosinophilic myocarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myocarditis characterized by a predominantly eosinophilic infiltrate may occur in association with malignancy, parasite infection, hypersensitivity myocarditis (HSM), endomyocardial fibrosis, and with the idiopathic hypereosinophilic syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/28/22986?source=see_link&amp;anchor=H8#H8\">",
"     \"Etiology and pathogenesis of myocarditis\", section on 'Hypersensitivity myocarditis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      HSM presents as sudden death or rapidly progressive heart failure sometimes with rash, fever and peripheral eosinophilia. Necrotizing eosinophilic myocarditis has an exceptionally poor prognosis with most cases diagnosed at autopsy.",
"     </li>",
"     <li>",
"      In contrast, eosinophilic myocarditis associated with the hypereosinophilic syndrome typically evolves over weeks to months. The presentation is usually biventricular heart failure, although arrhythmias may lead to sudden death.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Treatment usually consists of high dose steroids and removal of the offending drug (in the case of HSM) or treatment of the underlying disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10874/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Sarcoid myocarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sarcoid myocarditis may respond to treatment with corticosteroids if given before the development of extensive fibrosis of the LV [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10874/abstract/67\">",
"     67",
"    </a>",
"    ]. It is less clear if steroid therapy prevents conduction disease or ventricular arrhythmias. Some recommend an implantable cardioverter-defibrillator (ICD) as primary therapy of ventricular tachycardia since there is a high rate of recurrence of ventricular tachycardia with antiarrhythmic drug therapy, even when guided by electrophysiologic testing [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10874/abstract/68\">",
"     68",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/19/17722?source=see_link\">",
"     \"Cardiac sarcoidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Celiac disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;A report from Italy suggests that celiac disease, which is often clinically unsuspected, accounts for as many as 5 percent of patients with autoimmune myocarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10874/abstract/69\">",
"     69",
"    </a>",
"    ]. Among nine such patients, none had classic gastrointestinal symptoms of celiac disease (recurrent abdominal pain, diarrhea, and weight loss), but all had iron deficiency anemia refractory to iron replacement. Cardiac function and arrhythmias improved following a gluten-free diet with or without immunosuppressive therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/28/22986?source=see_link&amp;anchor=H9#H9\">",
"     \"Etiology and pathogenesis of myocarditis\", section on 'Celiac disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;With the exception of disease due to specific disorders such as sarcoidosis and celiac disease, the treatment of myocarditis remains largely supportive as described in the next section [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10874/abstract/49\">",
"     49",
"    </a>",
"    ]. Immunosuppressive therapy has not been predictably effective in acute lymphocytic myocarditis, perhaps due in part to a relatively high rate of recovery with heart failure therapy, and more data are required to assess the role of antiviral drugs, such as the interferons. More data are also required to determine if the absence of viral genomes on endomyocardial biopsy identifies patients who are more likely to improve with immunosuppressive therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10874/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Immunosuppressive therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     NONSPECIFIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several nonspecific measures are important, including treatment of HF and arrhythmias according to current guidelines, avoidance of exercise, and in select cases, anticoagulation:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Heart failure therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heart failure should be treated with a low sodium diet, cautious diuresis as needed, and angiotensin converting enzyme (ACE) inhibitors. A study in murine coxsackievirus myocarditis showed that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/59/9145?source=see_link\">",
"     captopril",
"    </a>",
"    administration on day three led to less myonecrosis and dystrophic calcification, suggesting benefits by mechanisms other than vasodilatation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10874/abstract/70\">",
"     70",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Beta blockers may also useful. In a murine model of coxsackievirus myocarditis, treatment with a nonselective beta blocker improved outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10874/abstract/71\">",
"     71",
"    </a>",
"    ]. In contrast,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    increased mortality in a mouse model of viral myocarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10874/abstract/72\">",
"     72",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12905?source=see_link\">",
"     \"Use of beta blockers in heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mechanical circulatory support with an intraaortic balloon pump or temporary LV assist device should be considered when HF is intractable or when cardiogenic shock does not respond to medical therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10874/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]. Several reports suggest that in some patients these devices can be used successfully as a bridge to spontaneous recovery in the setting of fulminant myocarditis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/34/15911?source=see_link\">",
"     \"Circulatory assist devices: Cardiopulmonary assist device and short-term left ventricular assist devices\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/36/13896?source=see_link\">",
"     \"Intraaortic balloon pump counterpulsation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Avoidance of exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physical activity should be",
"    <strong>",
"     restricted",
"    </strong>",
"    to reduce the work of the heart during the acute phase of myocarditis, especially when there is fever, active systemic infection, or HF. The efficacy of this recommendation has been demonstrated in animal models. Exercise in murine coxsackievirus infection increased viral replication in the heart and heart weight compared to controls [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10874/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Electrocardiographic monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electrocardiographic monitoring can permit early detection of asymptomatic yet potentially life-threatening arrhythmias",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    conduction defects. For this reason, it is recommended that patients with acute and often unstable myocarditis be admitted to the hospital.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Arrhythmias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with myocarditis can develop both tachy- and bradyarrhythmias. Because these arrhythmias often resolve after the acute phase of myocarditis, therapy is generally supportive.",
"   </p>",
"   <p>",
"    The 2006 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/European",
"    </span>",
"    Society of Cardiology",
"    <span class=\"nowrap\">",
"     (ACC/AHA/ESC)",
"    </span>",
"    guidelines for the management of ventricular arrhythmias and the prevention of sudden cardiac death included recommendations for the management of arrhythmias associated with myocarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10874/abstract/76\">",
"     76",
"    </a>",
"    ]. Our suggested approach is in broad agreement with those guidelines:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antiarrhythmic therapy should not be given for asymptomatic atrial and ventricular premature beats or for asymptomatic nonsustained arrhythmias.",
"     </li>",
"     <li>",
"      Supraventricular tachycardias (SVTs) can induce or aggravate HF. For sustained, symptomatic SVT, restoration of sinus rhythm is the recommended initial approach. For recurrent sustained SVT, options include rate control therapy and antiarrhythmic therapy. The specific approach to restoring sinus rhythm, controlling the ventricular rate, and selecting an antiarrhythmic drug depends upon the arrhythmia and the overall clinical scenario. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/20/6473?source=see_link\">",
"       \"Overview of the acute management of tachyarrhythmias\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39481?source=see_link\">",
"       \"Clinical manifestations, diagnosis, and evaluation of narrow QRS complex tachycardias\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Sustained ventricular arrhythmias should be treated with urgent cardioversion, and recurrent arrhythmias should be treated with antiarrhythmic drugs. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/19/31034?source=see_link\">",
"       \"Approach to the diagnosis and treatment of wide QRS complex tachycardias\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Symptomatic nonsustained ventricular tachycardia can be treated with antiarrhythmic drugs. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/26/22952?source=see_link\">",
"       \"Management of nonsustained ventricular tachycardia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      When antiarrhythmic therapy is necessary, options include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"       dofetilide",
"      </a>",
"      (with precautions for potential proarrhythmia), and in patients without class IV HF, cautious use of beta blockers or calcium channel blockers. Due to the proarrhythmic and negative inotropic effects, other class I and class III antiarrhythmic drugs are generally avoided in patients with acute myocarditis.",
"     </li>",
"     <li>",
"      ICD implantation can be beneficial in patients with life-threatening ventricular arrhythmias who are not in the acute phase of myocarditis, who are receiving chronic optimal medical therapy, and who have reasonable expectation of survival with a good functional status for more than one year. Data are lacking regarding specific late risks of VT and sudden cardiac arrest in subjects with myocarditis who present with VT or sudden cardiac arrest, so this recommendation is based solely upon expert opinion. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43385?source=see_link\">",
"       \"Role of implantable cardioverter-defibrillators for the secondary prevention of sudden cardiac death\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Complete heart block",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      symptomatic bradycardia are indications for pacing during the acute phase of myocarditis. This conduction abnormality is often transient; as a result, use of a temporary pacemaker should be the first step.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thromboembolic complications can occur when HF is severe or protracted. Echocardiography is especially useful for the detection of intracardiac thrombi which, if present, are an indication for anticoagulant therapy. Anticoagulation may also be advisable as a preventive measure as in other causes of chronic CHF. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/56/7048?source=see_link\">",
"     \"Indications for antithrombotic therapy in heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We recommend",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    to patients with atrial fibrillation and to",
"    <strong>",
"     stable",
"    </strong>",
"    patients in sinus rhythm who fulfill the following criteria:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Symptomatic HF with an LVEF below 20.",
"     </li>",
"     <li>",
"      Minimal risk factors for hemorrhage.",
"     </li>",
"     <li>",
"      A stable hemodynamic profile without evidence of liver synthetic dysfunction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The optimal degree of anticoagulation has not been established. We aim for a moderate degree of anticoagulation &mdash; INR (International Normalized Ratio) between 2.0 and 3.0 &mdash; to minimize the risk of bleeding. Once the patient is stable, the INR is measured monthly. We reassess the safety of continued anticoagulation if the heart disease progresses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several other therapeutic modalities may apply to selected patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Oxygen administration is advisable in acutely ill patients, since hypoxia aggravates experimental viral myocarditis [",
"      <a class=\"abstract\" href=\"UTD.htm?10/39/10874/abstract/77\">",
"       77",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Alcohol restriction to at most one alcoholic drink per day, since heavy alcohol intake may enhance the severity of the myocarditis [",
"      <a class=\"abstract\" href=\"UTD.htm?10/39/10874/abstract/78\">",
"       78",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/33/31258?source=see_link\">",
"       \"Cardiovascular benefits and risks of moderate alcohol consumption\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cardiac transplantation in patients with chronic myocarditis presenting as an intractable cardiomyopathy with persistent HF. Although a small case series (n=12) of patients with active lymphocytic myocarditis at the time of transplant suggested an increased surgical risk in such patients [",
"      <a class=\"abstract\" href=\"UTD.htm?10/39/10874/abstract/79\">",
"       79",
"      </a>",
"      ], patients with biopsy-proven myocarditis (n=142) in the much larger United Network for Organ Sharing (UNOS) registry did at least as well as other cardiac transplantation patients over one-year follow-up [",
"      <a class=\"abstract\" href=\"UTD.htm?10/39/10874/abstract/80\">",
"       80",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/15/22775?source=see_link\">",
"       \"Prognosis after cardiac transplantation\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A number of experimental therapies have been evaluated in rodent models of myocarditis including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10874/abstract/81\">",
"     81",
"    </a>",
"    ]; anti-tumor necrosis factor antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10874/abstract/82\">",
"     82",
"    </a>",
"    ]; opiate receptor antagonists [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10874/abstract/83\">",
"     83",
"    </a>",
"    ]; and the nasal administration of cardiac myosin, which induces antigen-specific tolerance and suppresses the autoimmune response to native cardiac myosin induced by viral infection [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10874/abstract/84\">",
"     84",
"    </a>",
"    ]. The relevance of these therapies to human disease remains to be determined.",
"   </p>",
"   <p>",
"    The possible beneficial effect of herbal remedies in viral myocarditis was evaluated in a Cochrane review [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10874/abstract/85\">",
"     85",
"    </a>",
"    ]. Forty randomized trials including 3448 patients were included; all trials were conducted and published in China. The methodologic quality of the trials was generally low. Significant effects on arrhythmia, cardiac enzymes,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cardiac function were seen in studies of three agents. Further study of these agents may be justified, but clinical use cannot be recommended at present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, most patients with acute myocarditis have partial or full clinical recovery. In some cases, however, the process may continue subclinically, eventually becoming severe enough to produce symptoms, often with DCM [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10874/abstract/9-11,15,86,87\">",
"     9-11,15,86,87",
"    </a>",
"    ]. The likelihood of these late complications is increased in patients who present with greatly diminished LV function.",
"   </p>",
"   <p>",
"    As a result, all patients with myocarditis should be followed, initially at intervals of one to three months. Physical activity, especially competitive sports, should be permitted only gradually, and their tolerance monitored. The examiner should be alert to persistent or recurring S3 and S4 gallops. Echocardiography or radionuclide angiography should be used for monitoring the size of the cardiac chambers and the LVEF. We assess cardiac function at one and six months and then yearly or as indicated by symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;As a result of the widespread use of vaccination in developed countries, myocarditis secondary to measles, rubella, mumps, poliomyelitis, and influenza is now rare. Similarly, the recognition of trichinellosis by meat inspection has all but eliminated this infection. It is possible that vaccines against other cardiotropic viruses may prevent viral myocarditis; this approach has been successful in mice [",
"    <a class=\"abstract\" href=\"UTD.htm?10/39/10874/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     O'Connell, JB. Diagnosis and medical treatment of inflammatory cardiomyopathy. In: Cardiovascular Medicine, Topol, E, Nissen, J (Eds), Lippincott-Raven, Philadelphia 1998.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10874/abstract/2\">",
"      Felker GM, Thompson RE, Hare JM, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 2000; 342:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10874/abstract/3\">",
"      Wentworth P, Jentz LA, Croal AE. Analysis of sudden unexpected death in southern Ontario, with emphasis on myocarditis. Can Med Assoc J 1979; 120:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10874/abstract/4\">",
"      Mason JW, O'Connell JB, Herskowitz A, et al. A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. N Engl J Med 1995; 333:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10874/abstract/5\">",
"      Hosenpud JD, McAnulty JH, Niles NR. Unexpected myocardial disease in patients with life threatening arrhythmias. Br Heart J 1986; 56:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10874/abstract/6\">",
"      Frustaci A, Chimenti C, Bellocci F, et al. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 1997; 96:1180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10874/abstract/7\">",
"      McNamara DM, Holubkov R, Starling RC, et al. Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy. Circulation 2001; 103:2254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10874/abstract/8\">",
"      Mendes LA, Picard MH, Dec GW, et al. Ventricular remodeling in active myocarditis. Myocarditis Treatment Trial. Am Heart J 1999; 138:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10874/abstract/9\">",
"      Miklozek CL, Kingsley EM, Crumpaker CS, et al. Serial cardiac function tests in myocarditis. Postgrad Med J 1986; 62:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10874/abstract/10\">",
"      Kearney MT, Cotton JM, Richardson PJ, Shah AM. Viral myocarditis and dilated cardiomyopathy: mechanisms, manifestations, and management. Postgrad Med J 2001; 77:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10874/abstract/11\">",
"      Liu PP, Mason JW. Advances in the understanding of myocarditis. Circulation 2001; 104:1076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10874/abstract/12\">",
"      Caforio AL, Goldman JH, Haven AJ, et al. Circulating cardiac-specific autoantibodies as markers of autoimmunity in clinical and biopsy-proven myocarditis. The Myocarditis Treatment Trial Investigators. Eur Heart J 1997; 18:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10874/abstract/13\">",
"      Lauer B, Schannwell M, K&uuml;hl U, et al. Antimyosin autoantibodies are associated with deterioration of systolic and diastolic left ventricular function in patients with chronic myocarditis. J Am Coll Cardiol 2000; 35:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10874/abstract/14\">",
"      Caforio AL, Vinci A, Iliceto S. Anti-heart autoantibodies in familial dilated cardiomyopathy. Autoimmunity 2008; 41:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10874/abstract/15\">",
"      Grogan M, Redfield MM, Bailey KR, et al. Long-term outcome of patients with biopsy-proved myocarditis: comparison with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1995; 26:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10874/abstract/16\">",
"      Goldberg, LR, Suk, J, Patton, KK, et al. Predictors of adverse outcome in biopsy-proven myocarditis (abstract). J Am Coll Cardiol 1999; 33:A850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10874/abstract/17\">",
"      McCarthy RE 3rd, Boehmer JP, Hruban RH, et al. Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis. N Engl J Med 2000; 342:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10874/abstract/18\">",
"      Cappola TP, Felker GM, Kao WH, et al. Pulmonary hypertension and risk of death in cardiomyopathy: patients with myocarditis are at higher risk. Circulation 2002; 105:1663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10874/abstract/19\">",
"      Lieberman EB, Hutchins GM, Herskowitz A, et al. Clinicopathologic description of myocarditis. J Am Coll Cardiol 1991; 18:1617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10874/abstract/20\">",
"      Amabile N, Fraisse A, Bouvenot J, et al. Outcome of acute fulminant myocarditis in children. Heart 2006; 92:1269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10874/abstract/21\">",
"      K&uuml;hl U, Pauschinger M, Seeberg B, et al. Viral persistence in the myocardium is associated with progressive cardiac dysfunction. Circulation 2005; 112:1965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10874/abstract/22\">",
"      Kindermann I, Kindermann M, Kandolf R, et al. Predictors of outcome in patients with suspected myocarditis. Circulation 2008; 118:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10874/abstract/23\">",
"      Frustaci A, Chimenti C, Calabrese F, et al. Immunosuppressive therapy for active lymphocytic myocarditis: virological and immunologic profile of responders versus nonresponders. Circulation 2003; 107:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10874/abstract/24\">",
"      Fuse K, Kodama M, Okura Y, et al. Predictors of disease course in patients with acute myocarditis. Circulation 2000; 102:2829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10874/abstract/25\">",
"      Sheppard R, Bedi M, Kubota T, et al. Myocardial expression of fas and recovery of left ventricular function in patients with recent-onset cardiomyopathy. J Am Coll Cardiol 2005; 46:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10874/abstract/26\">",
"      Nishii M, Inomata T, Takehana H, et al. Serum levels of interleukin-10 on admission as a prognostic predictor of human fulminant myocarditis. J Am Coll Cardiol 2004; 44:1292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10874/abstract/27\">",
"      Kodama M, Matsumoto Y, Fujiwara M, et al. A novel experimental model of giant cell myocarditis induced in rats by immunization with cardiac myosin fraction. Clin Immunol Immunopathol 1990; 57:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10874/abstract/28\">",
"      Cooper LT Jr, Berry GJ, Shabetai R. Idiopathic giant-cell myocarditis--natural history and treatment. Multicenter Giant Cell Myocarditis Study Group Investigators. N Engl J Med 1997; 336:1860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10874/abstract/29\">",
"      Rose NR, Neumann DA, Herskowitz A. Coxsackievirus myocarditis. Adv Intern Med 1992; 37:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10874/abstract/30\">",
"      Kishimoto C, Crumpacker CS, Abelmann WH. Ribavirin treatment of murine coxsackievirus B3 myocarditis with analyses of lymphocyte subsets. J Am Coll Cardiol 1988; 12:1334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10874/abstract/31\">",
"      Kishimoto C, Crumpacker CS, Abelmann WH. Prevention of murine coxsackie B3 viral myocarditis and associated lymphoid organ atrophy with recombinant human leucocyte interferon alpha A/D. Cardiovasc Res 1988; 22:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10874/abstract/32\">",
"      Matsumori A, Tomioka N, Kawai C. Protective effect of recombinant alpha interferon on coxsackievirus B3 myocarditis in mice. Am Heart J 1988; 115:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10874/abstract/33\">",
"      Yamamoto N, Shibamori M, Ogura M, et al. Effects of intranasal administration of recombinant murine interferon-gamma on murine acute myocarditis caused by encephalomyocarditis virus. Circulation 1998; 97:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10874/abstract/34\">",
"      Ray CG, Icenogle TB, Minnich LL, et al. The use of intravenous ribavirin to treat influenza virus-associated acute myocarditis. J Infect Dis 1989; 159:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10874/abstract/35\">",
"      K&uuml;hl U, Pauschinger M, Schwimmbeck PL, et al. Interferon-beta treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction. Circulation 2003; 107:2793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10874/abstract/36\">",
"      Daliento L, Calabrese F, Tona F, et al. Successful treatment of enterovirus-induced myocarditis with interferon-alpha. J Heart Lung Transplant 2003; 22:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10874/abstract/37\">",
"      Tomioka N, Kishimoto C, Matsumori A, Kawai C. Effects of prednisolone on acute viral myocarditis in mice. J Am Coll Cardiol 1986; 7:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10874/abstract/38\">",
"      Monrad ES, Matsumori A, Murphy JC, et al. Therapy with cyclosporine in experimental murine myocarditis with encephalomyocarditis virus. Circulation 1986; 73:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10874/abstract/39\">",
"      Padalko E, Verbeken E, Matthys P, et al. Mycophenolate mofetil inhibits the development of Coxsackie B3-virus-induced myocarditis in mice. BMC Microbiol 2003; 3:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10874/abstract/40\">",
"      Mason JW, Billingham ME, Ricci DR. Treatment of acute inflammatory myocarditis assisted by endomyocardial biopsy. Am J Cardiol 1980; 45:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10874/abstract/41\">",
"      Jones SR, Herskowitz A, Hutchins GM, Baughman KL. Effects of immunosuppressive therapy in biopsy-proved myocarditis and borderline myocarditis on left ventricular function. Am J Cardiol 1991; 68:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10874/abstract/42\">",
"      Maisch B, Sch&ouml;nian U, Hengstenberg C, et al. Immunosuppressive treatment in autoreactive myocarditis--results from a controlled trial. Postgrad Med J 1994; 70 Suppl 1:S29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10874/abstract/43\">",
"      O'Connell JB, Mason JW. Diagnosing and treating active myocarditis. West J Med 1989; 150:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10874/abstract/44\">",
"      Wojnicz R, Nowalany-Kozielska E, Wojciechowska C, et al. Randomized, placebo-controlled study for immunosuppressive treatment of inflammatory dilated cardiomyopathy: two-year follow-up results. Circulation 2001; 104:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10874/abstract/45\">",
"      Frustaci A, Russo MA, Chimenti C. Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study. Eur Heart J 2009; 30:1995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10874/abstract/46\">",
"      Aretz HT, Billingham ME, Edwards WD, et al. Myocarditis. A histopathologic definition and classification. Am J Cardiovasc Pathol 1987; 1:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10874/abstract/47\">",
"      Baughman KL. Diagnosis of myocarditis: death of Dallas criteria. Circulation 2006; 113:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10874/abstract/48\">",
"      Parrillo JE. Inflammatory cardiomyopathy (myocarditis): which patients should be treated with anti-inflammatory therapy? Circulation 2001; 104:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10874/abstract/49\">",
"      Magnani JW, Dec GW. Myocarditis: current trends in diagnosis and treatment. Circulation 2006; 113:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10874/abstract/50\">",
"      M&uuml;ller J, Wallukat G, Dandel M, et al. Immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy. Circulation 2000; 101:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10874/abstract/51\">",
"      Wallukat G, M&uuml;ller J, Hetzer R. Specific removal of beta1-adrenergic autoantibodies from patients with idiopathic dilated cardiomyopathy. N Engl J Med 2002; 347:1806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10874/abstract/52\">",
"      Staudt A, B&ouml;hm M, Knebel F, et al. Potential role of autoantibodies belonging to the immunoglobulin G-3 subclass in cardiac dysfunction among patients with dilated cardiomyopathy. Circulation 2002; 106:2448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10874/abstract/53\">",
"      Staudt A, D&ouml;rr M, Staudt Y, et al. Role of immunoglobulin G3 subclass in dilated cardiomyopathy: results from protein A immunoadsorption. Am Heart J 2005; 150:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10874/abstract/54\">",
"      Vignola PA, Aonuma K, Swaye PS, et al. Lymphocytic myocarditis presenting as unexplained ventricular arrhythmias: diagnosis with endomyocardial biopsy and response to immunosuppression. J Am Coll Cardiol 1984; 4:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10874/abstract/55\">",
"      Robinson JL, Hartling L, Crumley E, et al. A systematic review of intravenous gamma globulin for therapy of acute myocarditis. BMC Cardiovasc Disord 2005; 5:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10874/abstract/56\">",
"      Gullestad L, Aass H, Fjeld JG, et al. Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. Circulation 2001; 103:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10874/abstract/57\">",
"      Costanzo-Nordin MR, Reap EA, O'Connell JB, et al. A nonsteroid anti-inflammatory drug exacerbates Coxsackie B3 murine myocarditis. J Am Coll Cardiol 1985; 6:1078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10874/abstract/58\">",
"      Rezkalla S, Khatib G, Khatib R. Coxsackievirus B3 murine myocarditis: deleterious effects of nonsteroidal anti-inflammatory agents. J Lab Clin Med 1986; 107:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10874/abstract/59\">",
"      Khatib R, Reyes MP, Smith F, et al. Enhancement of coxsackievirus B4 virulence by indomethacin. J Lab Clin Med 1990; 116:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10874/abstract/60\">",
"      Drucker NA, Colan SD, Lewis AB, et al. Gamma-globulin treatment of acute myocarditis in the pediatric population. Circulation 1994; 89:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10874/abstract/61\">",
"      McNamara DM, Rosenblum WD, Janosko KM, et al. Intravenous immune globulin in the therapy of myocarditis and acute cardiomyopathy. Circulation 1997; 95:2476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10874/abstract/62\">",
"      Litovsky SH, Burke AP, Virmani R. Giant cell myocarditis: an entity distinct from sarcoidosis characterized by multiphasic myocyte destruction by cytotoxic T cells and histiocytic giant cells. Mod Pathol 1996; 9:1126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10874/abstract/63\">",
"      Menghini VV, Savcenko V, Olson LJ, et al. Combined immunosuppression for the treatment of idiopathic giant cell myocarditis. Mayo Clin Proc 1999; 74:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10874/abstract/64\">",
"      Cooper LT Jr, Hare JM, Tazelaar HD, et al. Usefulness of immunosuppression for giant cell myocarditis. Am J Cardiol 2008; 102:1535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10874/abstract/65\">",
"      Moloney ED, Egan JJ, Kelly P, et al. Transplantation for myocarditis: a controversy revisited. J Heart Lung Transplant 2005; 24:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10874/abstract/66\">",
"      Cooper LT, Zehr KJ. Biventricular assist device placement and immunosuppression as therapy for necrotizing eosinophilic myocarditis. Nat Clin Pract Cardiovasc Med 2005; 2:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10874/abstract/67\">",
"      Kim JS, Judson MA, Donnino R, et al. Cardiac sarcoidosis. Am Heart J 2009; 157:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10874/abstract/68\">",
"      Winters SL, Cohen M, Greenberg S, et al. Sustained ventricular tachycardia associated with sarcoidosis: assessment of the underlying cardiac anatomy and the prospective utility of programmed ventricular stimulation, drug therapy and an implantable antitachycardia device. J Am Coll Cardiol 1991; 18:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10874/abstract/69\">",
"      Frustaci A, Cuoco L, Chimenti C, et al. Celiac disease associated with autoimmune myocarditis. Circulation 2002; 105:2611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10874/abstract/70\">",
"      Rezkalla S, Kloner RA, Khatib G, Khatib R. Effect of delayed captopril therapy on left ventricular mass and myonecrosis during acute coxsackievirus murine myocarditis. Am Heart J 1990; 120:1377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10874/abstract/71\">",
"      Tominaga M, Matsumori A, Okada I, et al. Beta-blocker treatment of dilated cardiomyopathy. Beneficial effect of carteolol in mice. Circulation 1991; 83:2021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10874/abstract/72\">",
"      Matsumori A, Igata H, Ono K, et al. High doses of digitalis increase the myocardial production of proinflammatory cytokines and worsen myocardial injury in viral myocarditis: a possible mechanism of digitalis toxicity. Jpn Circ J 1999; 63:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10874/abstract/73\">",
"      Rockman HA, Adamson RM, Dembitsky WP, et al. Acute fulminant myocarditis: long-term follow-up after circulatory support with left ventricular assist device. Am Heart J 1991; 121:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10874/abstract/74\">",
"      Chen JM, Spanier TB, Gonzalez JJ, et al. Improved survival in patients with acute myocarditis using external pulsatile mechanical ventricular assistance. J Heart Lung Transplant 1999; 18:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10874/abstract/75\">",
"      TILLES JG, ELSON SH, SHAKA JA, et al. EFFECTS OF EXERCISE ON COXSACKIE A9 MYOCARDITIS IN ADULT MICE. Proc Soc Exp Biol Med 1964; 117:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10874/abstract/76\">",
"      European Heart Rhythm Association, Heart Rhythm Society, Zipes DP, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol 2006; 48:e247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10874/abstract/77\">",
"      PEARCE JM. Heart disease and filtrable viruses. Circulation 1960; 21:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10874/abstract/78\">",
"      Miller, H, Abelmann, WH. Effects of dietary ethanol upon experimental Trypanosomal (T. cruzi) myocarditis. Proc Soc Exp Biol Med 1967; 126:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10874/abstract/79\">",
"      O'Connell JB, Dec GW, Goldenberg IF, et al. Results of heart transplantation for active lymphocytic myocarditis. J Heart Transplant 1990; 9:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10874/abstract/80\">",
"      O'Connell JB, Breen TJ, Hosenpud JD. Heart transplantation in dilated heart muscle disease and myocarditis. Eur Heart J 1995; 16 Suppl O:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10874/abstract/81\">",
"      Dong R, Liu P, Wee L, et al. Verapamil ameliorates the clinical and pathological course of murine myocarditis. J Clin Invest 1992; 90:2022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10874/abstract/82\">",
"      Yamada T, Matsumori A, Sasayama S. Therapeutic effect of anti-tumor necrosis factor-alpha antibody on the murine model of viral myocarditis induced by encephalomyocarditis virus. Circulation 1994; 89:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10874/abstract/83\">",
"      Kishimoto C, Takada H, Hiraoka Y, Shiraki K. Effects of naloxone, an opiate receptor antagonist, on coxsackievirus B3 myocarditis in the mouse. Cardiovasc Res 1995; 29:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10874/abstract/84\">",
"      Wang Y, Afanasyeva M, Hill SL, et al. Nasal administration of cardiac myosin suppresses autoimmune myocarditis in mice. J Am Coll Cardiol 2000; 36:1992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10874/abstract/85\">",
"      Liu JP, Yang M, Du XM. Herbal medicines for viral myocarditis. Cochrane Database Syst Rev 2004; :CD003711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10874/abstract/86\">",
"      Murphy JG, Wright RS, Bruce GK, et al. Eosinophilic-lymphocytic myocarditis after smallpox vaccination. Lancet 2003; 362:1378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10874/abstract/87\">",
"      Dec GW Jr, Palacios IF, Fallon JT, et al. Active myocarditis in the spectrum of acute dilated cardiomyopathies. Clinical features, histologic correlates, and clinical outcome. N Engl J Med 1985; 312:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/39/10874/abstract/88\">",
"      Matsumori A, Crumpacker CS, Abelmann WH, Kawai C. Virus vaccine and passive immunization for the prevention of viral myocarditis in mice. Jpn Circ J 1987; 51:1362.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4935 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-222.190.118.195-07BE0D3610-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_39_10874=[""].join("\n");
var outline_f10_39_10874=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Role of autoantibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Lymphocytic, presumably viral myocarditis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Fulminant myocarditis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Persistence of viral genome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Role of serologic markers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Giant cell myocarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Recent-onset idiopathic DCM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SPECIFIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Lymphocytic myocarditis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Antiviral therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Immunosuppressive therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - IVIG",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - NSAIDs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Acute, idiopathic DCM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Giant cell myocarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Eosinophilic myocarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Sarcoid myocarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Celiac disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      NONSPECIFIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Heart failure therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Avoidance of exercise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Electrocardiographic monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/4935\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4935|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/13/2270\" title=\"figure 1\">",
"      Viral infection cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/5/5213\" title=\"figure 2\">",
"      Myocarditis versus IDC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/42/40621\" title=\"figure 3\">",
"      Outcome fulminant myocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4935|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/51/14139\" title=\"table 1\">",
"      Treatable causes of myocarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/2/3117\" title=\"table 2\">",
"      Methods to assess cardiovascular disability",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/19/31034?source=related_link\">",
"      Approach to the diagnosis and treatment of wide QRS complex tachycardias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/19/17722?source=related_link\">",
"      Cardiac sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/33/31258?source=related_link\">",
"      Cardiovascular benefits and risks of moderate alcohol consumption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/34/15911?source=related_link\">",
"      Circulatory assist devices: Cardiopulmonary assist device and short-term left ventricular assist devices",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/16/26889?source=related_link\">",
"      Clinical manifestations and diagnosis of myocarditis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39481?source=related_link\">",
"      Clinical manifestations, diagnosis, and evaluation of narrow QRS complex tachycardias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/26/7592?source=related_link\">",
"      Endomyocardial biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/28/22986?source=related_link\">",
"      Etiology and pathogenesis of myocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/56/7048?source=related_link\">",
"      Indications for antithrombotic therapy in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/36/13896?source=related_link\">",
"      Intraaortic balloon pump counterpulsation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/26/22952?source=related_link\">",
"      Management of nonsustained ventricular tachycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/60/41927?source=related_link\">",
"      Myopericarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/59/22456?source=related_link\">",
"      Non-coronary cardiac manifestations of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/20/6473?source=related_link\">",
"      Overview of the acute management of tachyarrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=related_link\">",
"      Overview of the therapy of heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/15/22775?source=related_link\">",
"      Prognosis after cardiac transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43385?source=related_link\">",
"      Role of implantable cardioverter-defibrillators for the secondary prevention of sudden cardiac death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12905?source=related_link\">",
"      Use of beta blockers in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_39_10875="Betamethasone vs dexamethasone2";
var content_f10_39_10875=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F80060&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F80060&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Odds ratio of selected adverse outcomes",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Outcome",
"       </td>",
"       <td class=\"subtitle1\">",
"        Betamethasone versus control",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dexamethasone versus control",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intraventricular hemorrhage",
"       </td>",
"       <td>",
"        0.63*",
"       </td>",
"       <td>",
"        0.76*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neonatal death",
"       </td>",
"       <td>",
"        0.44*",
"       </td>",
"       <td>",
"        0.73",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Periventricular leukomalacia",
"       </td>",
"       <td>",
"        0.67",
"       </td>",
"       <td>",
"        0.63",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Retinopathy of prematurity",
"       </td>",
"       <td>",
"        1.16",
"       </td>",
"       <td>",
"        1.12",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Difference between study drug and controls was statistically significant.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Lee, BH, Stoll, BJ, McDonald, SA, et al. Pediatrics 2006; 117:1503.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_39_10875=[""].join("\n");
var outline_f10_39_10875=null;
var title_f10_39_10876="Local recurr breast CA in pts with occult primary breast CA";
var content_f10_39_10876=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F67113&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F67113&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Local recurrence of breast cancer in patients with occult primary breast cancer not undergoing local therapy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Author, year",
"       </td>",
"       <td class=\"subtitle1\">",
"        Breast failures (percent)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Delay in months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Atkins H; 1960",
"       </td>",
"       <td>",
"        5/9 (56)",
"       </td>",
"       <td>",
"        9 to 17",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Feuerman L; 1962",
"       </td>",
"       <td>",
"        0/1 (0)",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Haagensen C; 1974",
"       </td>",
"       <td>",
"        3/5 (60)",
"       </td>",
"       <td>",
"        5 to 64",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Kemeny M; 1986",
"       </td>",
"       <td>",
"        0/7 (0)",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Campana F; 1989",
"       </td>",
"       <td>",
"        2/2 (100)",
"       </td>",
"       <td>",
"        9 to 67",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ellerbroek N; 1990",
"       </td>",
"       <td>",
"        7/13 (54)",
"       </td>",
"       <td>",
"        11 to 47",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Merson M; 1992",
"       </td>",
"       <td>",
"        9/17 (53)",
"       </td>",
"       <td>",
"        2 to 34",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Van Ooijen B; 1993",
"       </td>",
"       <td>",
"        3/14 (21)",
"       </td>",
"       <td>",
"        16 to 56",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fouroudi F; 2000",
"       </td>",
"       <td>",
"        5/6 (83)",
"       </td>",
"       <td>",
"        7 (median)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Feigenberg S; 2003",
"       </td>",
"       <td>",
"        0/4 (0)",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Blanchard D; 2004",
"       </td>",
"       <td>",
"        12/16 (75)",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Total",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         46/94 (49)",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         -",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_39_10876=[""].join("\n");
var outline_f10_39_10876=null;
var title_f10_39_10877="Bow-legs DDx";
var content_f10_39_10877=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F69378&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F69378&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of bowed legs",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Condition",
"       </td>",
"       <td class=\"subtitle1\">",
"        Possible clues to the diagnosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Physiologic bowing",
"       </td>",
"       <td>",
"        Age &lt;2 years; bilateral and symmetric; involves the femurs and tibias; normal stature; no lateral thrust during ambulation; improves with age",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pathologic bowing",
"       </td>",
"       <td>",
"        Short stature, intercondylar distance &gt;6 cm when the legs are held with the patella facing forward and the medial malleoli touching",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Blount disease",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        Asymmetry; focal angulation of proximal tibia; lateral thrust during ambulation; radiographs with medial beaking and downward slope of proximal tibial metaphysis and epiphysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"2\">",
"        Rickets",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Nutritional rickets",
"       </td>",
"       <td class=\"sublist_other\">",
"        Breast-fed infant with inadequate supplementation of vitamin D; decreased serum calcium and/or vitamin D; widened physes and flared metaphyses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        X-linked dominant hypophosphatemic rickets (OMIM #307800)",
"       </td>",
"       <td class=\"sublist_other\">",
"        Growth retardation, rachitic and osteomalacic bone disease, hypophosphatemia, renal defects in phosphate resorption and vitamin D metabolism; widened physes and flared metaphyses may or may not be present",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Skeletal dysplasia",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        Characteristic clinical and radiographic features vary according to the dysplasia. Most children with skeletal dysplasia do not present solely with bowed legs. Some examples of additional manifestations are provided below.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Achondroplasia (OMIM #100800)",
"       </td>",
"       <td class=\"sublist_other\">",
"        Short stature; rhizomelic shortening of the limbs; frontal bossing; midface hypoplasia; lumbar lordosis; elongated fibula; trident hand",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Pseudoachondroplasia (OMIM #177170); associated with knock-knees in some patients",
"       </td>",
"       <td class=\"sublist_other\">",
"        Autosomal dominant inheritance; short-limb dwarfism with onset by 2 years; joint laxity; vertebral anomalies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Metaphyseal chondrodysplasia (multiple types)",
"       </td>",
"       <td class=\"sublist_other\">",
"        Persistent bowing and short stature",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Multiple epiphyseal dysplasia syndrome (OMIM #132400)",
"       </td>",
"       <td class=\"sublist_other\">",
"        Autosomal dominant inheritance; mild short-limb dwarfism; brachydactyly; small, irregular epiphyses on radiographs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Cartilage hair hypoplasia (OMIM #250250)",
"       </td>",
"       <td class=\"sublist_other\">",
"        Autosomal recessive inheritance; short-limb dwarfism; fine, sparse hair; sparse eyebrows, eyelashes, and beard; short hands",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"2\">",
"        Asymmetric growth",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Fracture",
"       </td>",
"       <td class=\"sublist_other\">",
"        History of fracture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Sepsis and DIC (eg, meningococcemia)",
"       </td>",
"       <td class=\"sublist_other\">",
"        History of infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Neoplasia (eg, focal fibrocartilaginous dysplasia of proximal tibial metaphysis)",
"       </td>",
"       <td class=\"sublist_other\">",
"        Progressive, unilateral deformity; radiolucent, well-circumscribed lesion, often with rim of reactive bone",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     OMIM: Online Mendelian Inheritance in Man.",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br/>",
"     <ol>",
"      <li>",
"       Schoenecker PL, Rich MM. The Lower Extremity. In: Lovell and Winter's Pediatric Orthopaedics, 6th ed, Morrissy RT, Weinstein SL (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.1158.",
"      </li>",
"      <li>",
"       The knee and leg. In: Mihran O. Tachdjian. Clinical Pediatric Orthopedics: The Art of Diagnosis and Principles of Management. Appleton &amp; Lange, Stamford, CT 1997. p.87.",
"      </li>",
"      <li>",
"       OMIM Online Mendelian Inheritance in Man (www.ncbi.nlm.nih.gov/omim/).",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_39_10877=[""].join("\n");
var outline_f10_39_10877=null;
var title_f10_39_10878="H pylori and gastric CA";
var content_f10_39_10878=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F73741&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F73741&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 537px\">",
"   <div class=\"ttl\">",
"    Possible mechanisms of Helicobacter pylori-induced gastric carcinogenesis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 517px; height: 292px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Blaser, MJ, Parsonnet, J, J Clin Invest 1994; 94:4.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_39_10878=[""].join("\n");
var outline_f10_39_10878=null;
var title_f10_39_10879="Rx asymptomatic chron severe MR";
var content_f10_39_10879=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F58148&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F58148&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    ACC/AHA Guidelines: Management strategy for asymptomatic patients with chronic severe mitral regurgitation (MR)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 419px; height: 501px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     LVEF: left ventricular ejection fraction; LVESD: left vendricular end-systolic dimension; AF: atrial fibrillation. Pulmonary hypertension is defined as pulmonary artery systolic pressure &gt;50 mmHg at rest or &gt;60 mmHg with exercise.",
"     <br>",
"      * Mitral valve repair may be performed in asymptomatic patients with normal left ventricular function if performed by an experienced surgical team and the likelihood of successful MV repair is greater than 90 percent.",
"      <br>",
"       <br>",
"        The 2012 European Society of Cardiology valvular heart disease guidelines recommend a similar management strategy. The key difference is&nbsp;that the LVESD cut-off used is &ge;45 mm in the ESC guidelines (versus &ge;40 mm in the ACC/AHA guidelines). In addition, the ESC guidelines state that&nbsp;mitral valve repair should be considered&nbsp;in asymptomatic patients without atrial fibrillation or pulmonary hypertension only&nbsp;if there is a high likelihood of durable repair at a low surgical risk and there is a flail leaflet and LVESD &ge;40mm. They also indicate that valve repair may be considered if left atrial volume is &ge;60 ML/m",
"        <sup>",
"         2",
"        </sup>",
"        BSA and sinus rhythm is present&nbsp;",
"        <strong>",
"         or",
"        </strong>",
"        pulmonary hypertension on exercise (pulmonary artery systolic pressure &ge;60 mmHg). Authors/Task Force Members, Vahanian A, Alfieri O, et al. Guidelines on the management of valvular heart disease (version 2012): The Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2012; 33:2451.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     <br>",
"      Adapted from Bonow RO, Carabello BA, Chatterjee K, et al. ACC/AHA 2006 Guidelines for the management of patients with valvular heart disease. A report of the American College of Cardiology / American Heart Association Task Force on Practice Guidelines (Writing committee to revise the 1998 guidelines for the management of patients with valvular heart disease). J Am Coll Cardiol 2006; 48:e1.",
"      <br>",
"       <br/>",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_39_10879=[""].join("\n");
var outline_f10_39_10879=null;
